

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Influence of Hospital Volume on Nephrectomy Mortality and Complications: A Systematic Review and Meta-Analysis Stratified by Surgical Type

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016833
Article Type:	Research
Date Submitted by the Author:	14-Mar-2017
Complete List of Authors:	Hsu, Ray; University of Cambridge, Department of Surgery, Academic Urology Group; Cambridge University Hospitals NHS Foundation Trust, Department of Urology Salika, Theodosia; University College London, Department of Epidemiology & Public Health, Health Behaviour Research Centre Maw, Jonathan; Cambridge University Hospitals NHS Foundation Trust, Department of Urology Lyratzopoulos, Georgios ; University College London, Department of Epidemiology & Public Health, Health Behaviour Research Centre Gnanapragasam, Vincent; University of Cambridge, Department of Surgery, Academic Urology Group; Cambridge University Hospitals NHS Foundation Trust, Department of Urology Armitage, James; Cambridge University Hospitals NHS Foundation Trust, Department of Urology
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Urology, Surgery
Keywords:	Hospital Volume, Nephrectomy, Nephrectomy Mortality, Nephrectomy Complications, Kidney & urinary tract disorders < UROLOGY, Urological tumours < UROLOGY

SCHOLARONE™
Manuscripts

1
2
3 **INFLUENCE OF HOSPITAL VOLUME ON NEPHRECTOMY MORTALITY AND COMPLICATIONS:**
4
5 **A SYSTEMATIC REVIEW AND META-ANALYSIS STRATIFIED BY SURGICAL TYPE**
6
7

8
9
10 Ray CJ Hsu,^{1,2} Theodosia Salika,³ Jonathan Maw,² Georgios Lyratzopoulos,³ Vincent J
11
12 Gnanapragasam,^{1,2,†} James N Armitage,^{2,†}
13
14

15
16
17 ¹Academic Urology Group, Department of Surgery, University of Cambridge, Cambridge
18
19 Biomedical Campus, Hills Road, Cambridge, UK, CB2 0QQ
20

21
22 ²Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS
23
24 Foundation Trust, Hills Road, Cambridge, UK, CB2 0QQ
25

26
27 ³Health Behaviour Research Centre, Department of Epidemiology and Public Health,
28
29 University College London, 1-19 Torrington Place, London, UK, WC1E 6BT
30

31 [†]Joint senior authors.
32
33

34
35
36 Corresponding author: Ray CJ Hsu
37

38 E-mail address: rch72@cam.ac.uk
39
40

41
42
43 Word count: 3,356
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives

The provision of complex surgery is increasingly centralised to high volume specialist hospitals. Evidence to support nephrectomy centralisation however has been inconsistent. We conducted a systematic review and meta-analysis to determine the association between hospital case volumes and perioperative outcomes in radical nephrectomy, partial nephrectomy and nephrectomy with venous thrombectomy.

Methods

Medline, Embase and the Cochrane Library were searched for relevant studies published between 1990 and 2016. Pooled effect estimates for nephrectomy mortality and complications were calculated for each nephrectomy type using the DerSimonian and Laird random-effect model. Sensitivity analyses were performed to examine the effects of heterogeneity on the pooled effect estimates by excluding studies with the heaviest weighting, lowest methodological score, and most likely to introduce misclassification bias.

Results

Some 226,657 patients from nineteen publications were included in our review. Of these, sixteen were used in the meta-analysis. Considerable heterogeneity was noted across the included studies.

High volume hospitals were correlated with a 26% and 52% reduction in mortality for radical nephrectomy (OR 0.74, 95% CI 0.61-0.90, $p < 0.01$) and nephrectomy with venous thrombectomy (OR 0.48, 95% CI 0.29-0.81, $p < 0.01$) respectively. In addition, radical

1
2
3 nephrectomy in high volume hospitals was associated with an 18% reduction in
4
5 complications (OR 0.82, 95% CI 0.73-0.92, $p<0.01$). No significant volume-outcome
6
7 relationship in mortality (OR 0.84, 95% CI 0.31-2.26, $p=0.73$) or complications (OR 0.85, 95%
8
9 CI 0.55-1.30, $p=0.44$) was observed for partial nephrectomy.
10
11
12
13

14 **Conclusions**

15
16
17 Our findings suggest that patients undergoing radical nephrectomy and nephrectomy with
18
19 venous thrombectomy have improved outcomes when treated by high volume hospitals.
20
21 Evidence of this in partial nephrectomy is however not yet clear and could be secondary to
22
23 the small patient number in our analyses. Further investigations are warranted to establish
24
25 the full potential of centralisation particularly as existing evidence is of low quality with
26
27 significant heterogeneity across studies.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STRENGTH & LIMITATIONS OF THIS STUDY

- This is a contemporary systematic review and meta-analysis of the associations between hospital case volumes and nephrectomy outcomes.
- Estimates were synthesised from seventeen studies, four folds greater than previous meta-analysis, and the study is the first to date to stratified results based on the types of nephrectomy to account for differences in technical complexity and rates of adverse outcomes.
- Multiple sensitivity and subgroup analyses were performed to assess the potential bias and confounders introduced.
- Current evidence in nephrectomy outcome-volume relationship is of low quality and considerable heterogeneity exists between studies in design, type of data used, outcomes measured and statistical methodologies.
- Our study highlights the limitations in existing evidence and suggests questions that should be addressed in future research.

INTRODUCTION

In recent years, there has been an emerging trend for the centralisation of complex operations in healthcare systems around the world [1–3]. This shift is supported by the growing research and evidence suggesting that hospitals and surgeons with high case loads have better patient outcomes [4–8]. Proponents argue that centralisation allows more effective use of clinical expertise and specialist equipment, and the increased exposure improves surgical skills and provides better training opportunities. Centralisation can also facilitate quicker adoption of care pathways, such as enhanced recovery, and may have more long-term financial sustainability for hospitals. However, differences in disease biology and surgical complexity mean that such a health service model may not be appropriate for all conditions.

Nephrectomy plays a key role in the management of many renal conditions and is often the only potentially curative treatment for renal cancer patients. Advancements in surgical techniques and technology have led to different nephrectomy types, such as partial nephrectomy, with different surgical complexities and outcomes [9,10]. With over 330,000 new annual renal cancer diagnoses worldwide and rising incidence in many countries, the number of nephrectomies being performed is also likely to increase [11,12]. It is therefore critical that health service providers understand the effects that organisational changes may have on patient outcomes. Despite the expansion on volume-outcome research, no consensus has been reached on the efficacy of centralising nephrectomy, and many uncertainties remain about its potential benefits. We present a contemporary systematic review and meta-analysis of the published literature on the association between hospital

1
2
3 case volumes and perioperative outcomes stratified by nephrectomy types. We hypothesise
4
5 that outcomes significantly improve with higher nephrectomy case volumes.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Search criteria & data extraction

The systematic review and meta-analysis was performed in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (S1 Appendix) [13]. Literature searches in Medline, Embase and the Cochrane Library were performed for relevant studies published between January 1990 and December 2016.

Studies published prior to 1990 were not considered as recent medical and surgical advancements would have limited their applicability to the modern healthcare system.

Databases were searched using medical subject heading (MeSH) terms and key words for nephrectomy, case volume and relevant outcomes (S2 Appendix). We considered only studies published in English and used primary data to examine nephrectomy outcomes in adult populations across two or more hospital case volumes. Only those investigating radical or partial nephrectomy were included and articles comprised solely of nephroureterectomy were excluded.

Two investigators (R.C.J.H and J.M.) independently reviewed all studies for validity and data extraction. References were also searched manually for additional relevant studies. Any disagreement between the two reviewers was resolved by discussion and consultation with a third reviewer (J.N.A.). Where only rates of outcomes were presented, these were applied to the case number to give the number of events, within the error of the published results. Study authors were contacted for further clarification if specific rates of outcomes and case numbers were not published [14,15].

1
2
3 As the cut-off values for hospital volume groups differed among studies, we used the
4
5 approach adopted by similar previous meta-analyses by evenly dichotomising groups into
6
7 low volume (LV) and high volume (HV) when articles presented a series of volume groupings
8
9 [16,17]. If a study presented an odd number of volume groups, the middle group was
10
11 categorised as LV.
12
13

14
15
16
17 Methodological quality and potential risk of bias were scored using a validated system
18
19 designed specifically for the evaluation of volume-outcome studies [18,19]. When studies
20
21 extracted data from the same source with overlap in the studied periods, we employed the
22
23 following rules to avoid duplicating populations: 1) studies with identical patient cohort but
24
25 examining different outcomes were considered and analysed separately; 2) studies that
26
27 derived data from older datasets were excluded in favour of the more contemporary cohort;
28
29 3) if the above rules were not applicable, studies with the lower methodological quality
30
31 scores were excluded; 4) where quality scores were equal, the study covering the longest
32
33 period was included.
34
35
36
37
38
39

40 **Quantitative data synthesis**

41
42 All statistical analyses were performed using Stata 14 [20]. Nephrectomy types were
43
44 categorised into radical nephrectomy, partial nephrectomy and nephrectomy with venous
45
46 thrombectomy and analysed separately. Studies involving multiple types of nephrectomies
47
48 were analysed based on the aforementioned groups, but if this was not feasible, they were
49
50 categories as radical nephrectomy. With the assumption that a distribution of effects exists
51
52 amongst studies, all pooled effect size were calculated using the DerSimonian and Laird
53
54 random-effect model, which provided more conservative estimates. Odds ratio (OR) and
55
56
57
58
59
60

1
2
3 95% confidence interval (CI) were calculated for each outcome measure using LV groups as
4
5 the reference. Pooled effect size was calculated for nephrectomy mortality and
6
7 complications.
8
9

10
11
12 When the meta-analysis demonstrated significantly better outcomes in HV hospitals, we
13
14 quantified the clinical effectiveness of centralisation by calculating the numbers needed to
15
16 treat, or in our case numbers needed to centralise (NNC). NNC represents the number of
17
18 cases that will need to be treated by HV hospitals in order to prevent one event.
19
20
21
22
23

24 **Heterogeneity**

25
26 As the DerSimonian and Laird model would have only accounted for some between-study
27
28 heterogeneity, we further quantified heterogeneity by calculating I^2 statistic. I^2 provides an
29
30 easily understood number, which describes the proportion of total variation in estimates
31
32 that is due to heterogeneity rather than chance [21]. Values of 25% or lower denote low
33
34 heterogeneity and values of 75% or greater denote considerable heterogeneity [22]. Meta-
35
36 regression was performed to explore the influence of potential explanatory variables on
37
38 heterogeneity including each study's publication year, country, data source, number of
39
40 patients and their demographics, number of hospitals, and threshold for HV hospitals.
41
42
43
44
45
46
47

48 **Publication bias**

49
50 Funnel plots were generated to investigate potential publication bias, and were enhanced to
51
52 include contours that divide the funnel into statistically significant and non-significant areas.
53
54
55 Funnel plot symmetry suggests low probability of publication bias and Harbord's modified
56
57
58
59
60

1
2
3 test was used to test for asymmetry [23]. Harbord's test reduces false positive rates when
4
5 applied to binary outcome data, especially when there is low between-study heterogeneity.
6
7 Trim and fill method was also performed to account for publication bias by adjusting the
8
9 meta-analysis to incorporate the theoretically missing studies [24].
10
11

12 13 14 15 **Sensitivity analysis**

16
17 To examine specific studies' effects on pooled effect size, sensitivity analyses were
18
19 performed by excluding individual studies and repeating the meta-analyses. We examined
20
21 the effects of studies with the heaviest weighting and studies with the lowest
22
23 methodological quality score. As there is currently no consensus on what nephrectomy case
24
25 volume is necessary to be considered as HV, we repeated our analyses by excluding studies
26
27 whose standardised HV categories overlapped most significantly with the standardised LV
28
29 categories in other studies to account for potential bias of misclassifying volume categories
30
31 in our dichotomy.
32
33
34
35
36
37

38 As secondary analyses, we additionally repeated the meta-analysis three further times with
39
40 different methods of dichotomising the volume groups to examine whether our initial
41
42 estimates would remain consistent. The methods of dichotomising were 1) lowest volume
43
44 categories and all others 2) even dichotomy and when studies present an odd number of
45
46 volume categories, the middle group was considered as HV 3) highest volume categories and
47
48 all others.
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Study selection & characteristics

From the 5,680 articles initially identified, 19 were included in the systematic review containing 226,657 patients from seven countries (Figure 1). For the meta-analysis, eleven studies with 201,506 patients examining radical nephrectomy was included while four studies of 23,617 patients and two studies of 1,249 patients examining partial nephrectomy and nephrectomy with venous thrombectomy were included respectively. Publication year ranged from 2002 to 2016, while cohort periods covered from 1993 to 2013.

Tables 1 summarises the characteristics of the included studies. Variations were observed in study designs including source of data and outcomes measured. Out of a possible score of 18, the median quality score from the included studies was 8.5 (interquartile range 8 – 9) with the majority of the studies failing to adequately address potential confounders including measuring the appropriateness of patient selection, adjusting for case-mix variations and accounting for differences in clinical risks and processes of care. Variable thresholds for HV hospitals were noted across the included studies.

Table 1. Characteristics and methodological summary of studies.

Reference	Study Characteristics								Outcomes Measured						Case Mix	Quality Score (18)
	Year	Country	Period	Data Type	No. of Patients	No. of Hospitals	Low ^a	High ^a	Mortality	Complications (breakdowns)	Transfusion	LOS	Conversions	Others		
Radical Nephrectomy																
Hjelle[25]	2016	Norway	2008-2013	Admin	3,273	40	20	40	+	-	-	-	+	-	Demographics, tumour stage, nephrectomy type	8
Becker[26]/Sun[27] ^b	2014 / 2012	USA	1998-2007	Admin	48,172	N/S	5	16	+	+ (17 events inc haemorrhage, cardiac arrest, infection, wound disruption, seroma, pneumothorax, VTE etc)	+	+	-	-	Demographics, co-morbidity, nephrectomy type, laparoscopy, payer/hospital type	9
Hanchanale[268]	2010	England	1998-2005	Admin	20,672	1,181	14	35	+	-	-	+	-	-	Demographics	9
Yasunaga[29]	2010	Japan	2006-2007	Admin	7,988	646	26	65	+	+ (11 events inc surgical site infection, UTI, VTE, sepsis, ileus, stroke, cardiac events, renal, failure, peritonitis etc)	-	-	-	-	Demographics, co-morbidity, laparoscopy, hospital type, tumour location	9
Mitchell[30]	2009	USA	2003-2007	Clinical	42,988	134	99/4.5yr	500/4.5yr	+	+ (not specified)	-	+	-	ICU admission	None	9
Yasunaga[14]	2008	Japan	2006-2007	Clinical	1,704	461	9	40	+	+ (wound infection, pneumonia, ileus, renal dysfunction, others)	-	-	-	OT, EBL	Demographics, co-morbidity, laparoscopy, tumour stage & location	11
Davenport[31]	2005	England	2004	Clinical	598	48	<1/mo	>1/mo	+	+ (12 events inc bleeding, bowel injury, GI bleed, renal failure, pneumothorax, VTE, MI, splenic injury etc)	+	-	+	OT	None	4
Keoghane[32]	2004	England	2001-2002	Clinical	263	25	5	6	-	+ (16 events inc renal failure, sepsis, wound infection, bowel injury, incisional hernia, perihaptic collection etc)	-	-	+	-	None	3
Taub[33]	2004	USA	1993-1997	Admin	16,858	962	14	34	+	-	-	+	-	-	Demographics, co-morbidity, admission acuity	8
Goodney[34]	2003	USA	1994-1999	Admin	58,990	3,292	6	33	-	-	-	+	-	Readmission	Demographics, co-morbidity, admission acuity	8
Birkmeyer[35]	2002	USA	1994-1999	Admin	58,990	3,292	6	33	+	-	-	-	-	-	Demographics, co-morbidity, admission acuity	7
Partial Nephrectomy																

1																	
2																	
3																	
4	Porpiglia[36]	2016	Italy	2009-2013	Clinical	285	22	49	50	-	-	-	-	-	Trifecta ^c	Tumour growth patter, EBL	6
5																	
6	Couapel[37]	2014	France	2010	Clinical	570	53	4/7mo	19/7mo	+	+ (medical and surgical events, not further specified)	-	+	+	OT, EBL, Totalisation, +ve margin	N/S	8
7																	
8																	
9	Monn[38]	2014	USA	2009-2011	Admin	17,583	322	13	35	-	+ (organ based complications not further specified, pain, seroma, shock, haematoma, hypotension, VTE, pneumothorax)	+	+	-	Hospital cost	Demographics, co-morbidity, payer, region, hospital type	9
10																	
11	Abouassaly[39]	2012	Canada	1998-2008	Admin	4,292	181	146/10yr	797/10yr	+	+ (not specified)	-	-	-	-	Demographics, co-morbidity, region	12
12																	
13	Taub[33]	2004	USA	1993-1997	Admin	1,172	962	14	34	+	-	-	+	-	-	Demographics, co-morbidity, admission acuity	8
14																	
15																	
16																	
17	Nephrectomy with Venous Thrombectomy																
18																	
19	Toren[40]	2013	Canada	1998-2008	Admin	816	120	N/S	N/S	+	+ (40 medical and surgical events inc MI, CHF, PE, infection, organ injury, pneumothorax etc)	+	-	-	-	Demographics, co-morbidity, region	11
20																	
21	Yap[15]	2012	Canada	1995-2004	Admin	433	N/S	2/10yr	8/10yr	+	-	-	-	-	-	Demographics	11
22																	

^aLow, cut-off value for lowest volume group; high, cut-off value for highest-volume group. Volume units are cases per year unless specified. ^bBecker and Sun were equal in the data source used, outcomes evaluated, periods covered and quality scores, but employed different analyses to evaluate the benefit of regionalisation and volume-outcome relationship in nephrectomy [26,27]. ^cTrifecta was defined as simultaneous absence of complications, negative surgical margins and ischemic time of <25 minutes. We therefore treated them as one single cohort, with no duplicates in our analysis. Admin: Administrative. N/S: Not specified. RN: Radical nephrectomy. PN: Partial nephrectomy. VTE: venous thromboembolism. MI: Myocardial infarction. CHF: Congestive heart failure. PE: Pulmonary embolism. UTI: Urinary tract infection. GI: Gastrointestinal. OT: Operating time. EBL: Estimated blood loss. ICU: Intensive care unit.

Mortality and Hospital Volumes

Post-operative mortality was the most frequently examined outcome, reported in fourteen studies. Ten studies reported mortality in radical nephrectomy [14,25–31,33], three in partial nephrectomy [33,37,39] and two in nephrectomy with venous thrombectomy [15,40]. The overall mortality was 1.59% (range 0.20-7.2) with mortality rates in HV and LV hospitals being 1.47% and 1.68% respectively.

Radical Nephrectomy

Meta-analysis demonstrated that patients who underwent radical nephrectomy in HV hospitals had a 26% reduction (OR 0.74, 95% CI 0.61-0.90, $p < 0.01$) in post-operative mortality, corresponding to a NNC of 234 (Figure 2A). Significant heterogeneity was observed (I^2 75.0%, $p < 0.01$). Meta-regression was performed to investigate the potential explanatory variables for heterogeneity, and only differences in the threshold values for HV hospitals were shown to be a significant contributor (S3 Appendix A). Subgroup analysis of the three studies examining exclusively of radical nephrectomies demonstrated a more pronounced reduction in post-operative mortality favouring HV hospitals (OR 0.62, 95% CI 0.53-0.71, $p < 0.01$) [14,30,33]. This corresponded to a lower NNC of 166 with little residual heterogeneity (I^2 0.0 %, $p = 0.40$). The overall funnel plot was visually asymmetrical particularly missing studies with effect estimates favouring LV hospitals (Figure 3A). However, the Harbord's modified test did not show significant asymmetry ($p = 0.40$) and "trim and fill" method did not change the initial estimate, indicating no clear evidence of publication bias. In sensitivity analyses, exclusion of the most heavily weighted study led to a similar pooled-effect estimate (OR 0.70, 95% CI 0.55-0.88, $p < 0.01$) [35]. Exclusion of the study with the lowest quality score also did not significantly alter our result (OR 0.74, 95% CI 0.61-0.91,

1
2
3 p<0.01) [31]. To examine the potential bias introduced by misclassification, two cohorts
4
5 were excluded [26,27,31]. This did not substantially change our pooled-effect estimate
6
7 either (OR 0.73, 95% CI 0.58-0.93, p=0.01). Overall, radical nephrectomies in HV hospitals
8
9 appeared to have significantly lower mortality.
10
11

12 13 14 15 *Partial Nephrectomy*

16
17 Meta-analysis showed that partial nephrectomy patients operated in HV hospitals had a 16%
18
19 reduction in post-operative mortality but this was not statistically significant (OR 0.84, 95%
20
21 CI 0.31-2.26, p=0.73) (Figure 2B). Moderate but non-significant heterogeneity was noted (I^2
22
23 36.84 %, p=0.21). Sensitivity analyses removing studies with the heaviest weighting [39] or
24
25 most likely to introduce misclassification bias [37] demonstrated reduced mortality
26
27 favouring HV hospitals, but these remained non-significant.
28
29
30
31
32

33 34 *Nephrectomy with Venous Thrombectomy*

35
36 Patients who underwent nephrectomy with venous thrombectomy in HV hospitals had a
37
38 52% reduction (OR 0.48, 95% CI 0.29-0.81, p<0.01) in short-term mortality compared to LV
39
40 hospitals (Figure 2C). This corresponded to a NNC of 25 with low heterogeneity (I^2 0.0 %,
41
42 p=0.50). Due to the small number of studies reporting this outcome, further testing of
43
44 heterogeneity and publication bias was not expected to generate meaningful results and this
45
46 was not attempted.
47
48
49
50
51

52 53 **Complications and Hospital Volumes**

54
55 Complication was the second most frequently investigated outcome, reported in ten studies.
56
57 Six studies reported complications in radical nephrectomy [26,27,29–32] and three in partial
58
59
60

1
2
3 nephrectomy [37–39]. Only one study examined volume-outcome relationship in
4
5 nephrectomy with venous thrombectomy and meta-analysis was therefore not appropriate
6
7 [40]. The overall complication rate was 16.26% (range 7.4-78). HV hospitals had complication
8
9 rates of 15.00% compared to 17.51% in LV hospitals.

14 15 *Radical Nephrectomy*

16
17 Meta-analysis showed a 18% reduction (OR 0.82, 95% CI 0.73-0.92, $p < 0.01$) in nephrectomy
18
19 complications in HV centres, corresponding to a NNC of 38 (Figure 4A). Significant
20
21 heterogeneity was noted (I^2 76.25%, $p < 0.01$), but none of the factors examined in meta-
22
23 regression significantly contributed to this (S3 Appendix B). Funnel plot was visually
24
25 asymmetrical, but using the “trim and fill” method to account for potentially missing studies
26
27 resulted in similar pooled-effect estimate (OR 0.81, 95% CI 0.72-0.91, $p < 0.01$) (Figure 3B).
28
29 Harbord’s test also did not find significant funnel plot asymmetry to suggest publication bias
30
31 ($p = 0.18$). Sensitivity analyses by removing studies with the lowest quality [32] or most likely
32
33 to introduce misclassification bias [31,32] did not significantly alter our initial result.
34
35
36 Excluding study with the heaviest weighting however led to a loss of significance in the
37
38 pooled-effect estimate, which however still demonstrated a 11% reduction in complications
39
40 in HV hospitals (OR 0.89, 95% CI 0.74-1.08, $p = 0.24$). Overall, radical nephrectomies
41
42 performed in HV hospitals appeared to have significantly lower complications compared to
43
44
45
46
47
48 LV hospitals.

52 53 *Partial Nephrectomy*

54
55 Partial nephrectomy patients operated in HV hospitals had a 15% reduction in complications,
56
57 but this was not statistically significant (OR 0.85, 95% CI 0.55-1.30, $p = 0.44$) (Figure 4B).
58
59
60

1
2
3 Significant heterogeneity was noted (I^2 94.80%, $p < 0.01$). Sensitivity analysis by removing
4
5 studies with the heaviest weighting [38] or most likely to introduce misclassification bias [37]
6
7 did not result in significance.
8
9

10 11 12 **Secondary analyses using different methods of dichotomising HV and LV** 13

14
15 As there is no consensus on what constituted HV hospitals in current evidence, simple
16
17 dichotomy of volume groups may introduce inherent bias to the estimates. Yet no
18
19 recommendation on how best to proceed in volume-outcome analysis presently exists.
20
21 In our secondary analyses, we consistently observed significantly lower risks of mortality for
22
23 both radical nephrectomy and nephrectomy with venous thrombectomy in HV hospitals
24
25 regardless how volumes were dichotomies (Table 2). The magnitudes of risk reductions were
26
27 more pronounced when higher thresholds for HV hospitals were considered particularly for
28
29 radical nephrectomy mortality. Partial nephrectomy mortality however continued to
30
31 demonstrate no significant association to volume even when dichotomies were comparing
32
33 the highest volume groups to all others.
34
35
36
37
38
39

40
41 Risks of radical nephrectomy complications remained significantly reduced in HV hospitals
42
43 when the dichotomy threshold for HV hospitals was increased, but the significance was lost
44
45 when the thresholds were lowered. Association between hospital volumes and partial
46
47 nephrectomy complications remained insignificant regardless of how HV was defined in our
48
49 dichotomy.
50
51
52
53
54
55
56
57
58
59
60

Table 2: Results of meta-analysis by using different methods of dichotomising volume groups.

	Lowest volume group vs. all others	Even dichotomy, middle group as HV	Even dichotomy, middle group as LV (Primary analysis)	Highest volume group vs. all others
Mortality				
Radical Nephrectomy	OR: 0.82 95%CI 0.71-0.94 p=0.01	OR: 0.83 95%CI 0.72-0.95 p<0.01	OR: 0.74 95%CI 0.61-0.90 p<0.01	OR: 0.72 95%CI 0.61-0.85 p<0.01
Partial Nephrectomy	OR: 0.48 95%CI 0.18-1.31 p=0.15	OR: 0.67 95%CI 0.17-2.75 p=0.58	OR: 0.84 95%CI 0.31-2.26 p=0.73	OR: 0.93 95%CI 0.31-2.77 p=0.90
Nephrectomy with Venous Thrombectomy	OR: 0.59 95%CI 0.35-0.99 p=0.045	OR: 0.46 95%CI 0.27-0.80 p<0.01	OR: 0.48 95%CI 0.29-0.81 p=0.01	OR: 0.48 95%CI 0.25-0.92 p=0.03
Complications				
Radical Nephrectomy	OR: 0.89 95%CI 0.78-1.01 p=0.07	OR: 0.84 95%CI 0.68-1.05 p=0.13	OR: 0.82 95%CI 0.73-0.92 p<0.01	OR: 0.82 95%CI 0.73-0.92 p<0.01
Partial Nephrectomy	OR: 0.82 95%CI 0.55-1.41 p=0.60	OR: 0.80 95%CI 0.47-1.36 p=0.40	OR: 0.85 95%CI 0.55-1.30 p=0.44	OR: 0.81 95%CI 0.53-1.24 p=0.33

DISCUSSION

Evidence on volume-outcome relationships in complex diseases and procedures has increased substantially in recent years. Many operations have been shown to have improved outcomes in HV centres, but this may not be uniform across all surgeries and no benefits have been associated to volume in percutaneous nephrolithotomy or appendicectomy [41–46]. This meta-analysis provides a contemporary review of the effects of centralisation in nephrectomy outcomes. It has revealed significant inverse associations between hospital case volumes for short-term mortality and complications for radical nephrectomies and nephrectomies with venous thrombectomies.

Considered individually, all but three studies in our review reported lack of associations between hospital volume and nephrectomy mortality [25,33,35]. However, such associations in favour of HV hospitals were apparent when considering the totality of the evidence particularly in radical nephrectomies and venous thrombectomies. This finding is consistent with the only other meta-analysis on nephrectomy volume-outcome relationship published in 2009 but includes four-fold greater number of studies [19]. Our meta-analysis demonstrates that the mortality benefit seen in radical nephrectomy may be relatively small requiring centralisation of 234 patients in order to avoid one death. However, the NNC decreased considerably to 166 in our sensitivity analyses. Coupled with the much lower NNC of 38 for radical nephrectomy complications, there is moderate evidence to support its centralisation.

Our analyses would be consistent with the “practice makes perfect” hypothesis for volume-outcome relationship [47]. Particularly, the reduction in mortality for nephrectomy with

1
2
3 venous thrombectomy, a technically challenging operation, was observed to be more
4
5 pronounced than that in radical nephrectomy with potentially one avoidable death for every
6
7 25 cases centralised to HV hospitals. However, similar trend was not seen in partial
8
9 nephrectomy, also considered technically complex. Partial nephrectomy has been
10
11 demonstrated to be a safe procedure with comparable short-term mortality and morbidity
12
13 profile to radical nephrectomy and at such the relatively small number of partial
14
15 nephrectomy patients in our meta-analysis might not have been sufficient to reveal the true
16
17 presence of a volume-outcome relationship, as evident in our wide confidence interval [48].
18
19 This may also explain the lack of significant association between partial nephrectomy
20
21 complications and hospital volumes. With its low mortality and morbidity rates, other
22
23 outcome measures such as ischaemic time and negative surgical margins, are likely to be
24
25 more appropriate quality markers in volume-outcome analysis. These have so far been
26
27 poorly evaluated in current studies.
28
29
30
31
32
33
34
35

36 Despite the strict inclusion criteria in our studies, we observed considerable heterogeneity,
37
38 especially in the meta-analyses of nephrectomy complications. One explanation for this is
39
40 the lack of standardised reporting of complications by individual studies. Harder endpoints
41
42 as previously discussed could have overcome this. Other more objective outcomes including
43
44 transfusion rate and length of stay were reported by four [26,27,31,38] and eight studies
45
46 [26–28,30,34,37,38,49] in our systematic review respectively, but they were not in adequate
47
48 numbers to be stratified by nephrectomy types or in sufficiently detailed data to perform
49
50 meta-analyses. In addition, variations in the threshold values for HV hospitals likely
51
52 contributed to the heterogeneity, although this was not evident in the meta-regression.
53
54
55
56
57
58
59
60

1
2
3 Results from the multiple sensitivity analyses to adjust for these differences have remained
4
5 robust and our study would therefore appear to be informative and relevant.
6
7

8
9
10 While there has been an expansion in the studies on nephrectomy volume-outcome
11
12 relationship, many questions continue to be unanswered. The proportion of nephrectomy
13
14 performed under laparoscopy or robotic assistance is growing [50,51]. There is however a
15
16 paucity of evidence specifically investigating this in the volume-outcome context with only
17
18 one study examining the differences in perioperative measures in robotic partial
19
20 nephrectomy [38]. Three other studies have adjusted surgical techniques in multivariable
21
22 regressions, but these did not directly demonstrate the effect of laparoscopic volumes on
23
24 surgical outcomes [14,26,29]. Due to the small study number and data quality, it was not
25
26 possible in this meta-analysis to further sub-stratify each nephrectomy type into open and
27
28 minimally invasive and our results should be interpreted taking this limitation into account.
29
30
31
32
33
34
35

36 Tumour characteristics including TNM stage and grades are well established to significantly
37
38 affect and predict nephrectomy mortality, but only two studies have so far adjusted for this
39
40 in their analyses [14,25]. Surgeon case volume and degree of specialisation also play
41
42 significant roles in determining operative outcome, and can be more important than hospital
43
44 case volume alone [43,52–54]. While not the focus of this study, no significant association
45
46 was found between surgeon volume and complications in radical nephrectomy [14], but 31%
47
48 and 16% reduction in mortality and complications respectively was observed in partial
49
50 nephrectomy in HV surgeons [39]. HV surgeons performing nephrectomy with venous
51
52 thrombectomy were also reported to have reduced risk of mortality [15], but this was not
53
54 observed in a subsequent study [40]. It would be of high interest to understand the
55
56
57
58
59
60

1
2
3 interactions between surgeon volume, surgical approach and oncological factors in the
4
5 volume-outcome relationship and may provide additional insights to selecting patients that
6
7 will benefit the most from nephrectomy centralisation, such as those with advanced disease.
8
9 Similarly, no study has examined the long-term benefits of centralising nephrectomy when
10
11 high volume centres have been demonstrated to increase oncological survival in other
12
13 cancer surgeries [55,56]. Results of this may further influence the recommendations for
14
15 nephrectomy centralisation and this is currently being explored in our ongoing work. Other
16
17 outcomes including long-term risks of chronic kidney disease and cardiovascular morbidities
18
19 and patient reported outcome measures may also provide more relevant and holistic
20
21 measurements of the potential efficacy of nephrectomy centralisation.
22
23
24
25
26
27
28

29 Our secondary analyses would suggest that a minimum volume threshold for nephrectomy
30
31 likely exist, and beyond that, risks of adverse outcomes may continue to decrease with
32
33 further increase in volume. An important limitation of this however is that this minimum
34
35 threshold cannot be objectively determined from the current evidence. Volume is also likely
36
37 to be a proxy marker of other specific care processes that may produce improved outcome,
38
39 such as access to nurse specialists and clinical trials [57]. Increasing volume alone in itself
40
41 may therefore not reduce adverse results. Future research should concentrate on identifying
42
43 the qualitative differences between providers in order for the contributing good practices to
44
45 be adopted by lesser performing centres.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CONCLUSIONS

Current evidence of the association between hospitals volumes and nephrectomy outcomes is of low quality with considerable heterogeneity amongst studies. Our meta-analyses have demonstrated significant reduction in mortality and complications for patients undergoing radical nephrectomy and nephrectomy with venous thrombectomy in HV hospitals. Evidence of this in partial nephrectomy is not yet clear but warrants further investigations.

For peer review only

ACKNOWLEDGMENTS

We would like to acknowledge Annie Herbert for providing valuable critiques of the methodologies.

For peer review only

CONTRIBUTORS

RCJH, VJG and JNA contributed to the study conception and design. RCJH, JM and JNA contributed to data acquisition and risk of bias assessment. RCJH, TS, GL, VJG, JNA contributed to statistical analysis, data interpretation and critical manuscript revision. RCJH contributed to drafting the manuscript. RCJH contributed to obtaining funding. GL, VJG and JNA contributed to supervision of the study.

FUNDING STATEMENT

This work was supported by Addenbrooke's Charitable Trust, the Royal College of Surgeons of England and the Urology Foundation.

COMPETING INTEREST STATEMENT

None declared.

DATA SHARING STATEMENT

No additional data are available.

REFERENCES

- 1 National Institute for Clinical Excellence. Guidance on cancer services: Improving outcomes in urological cancers. London: 2002.
- 2 Cooperberg MR, Modak S, Konety BR. Trends in regionalization of inpatient care for urological malignancies, 1988 to 2002. *J Urol* 2007;**178**:2103–8.
- 3 Boudourakis LD, Wang TS, Roman SA, *et al*. Evolution of the surgeon-volume, patient-outcome relationship. *Ann Surg* 2009;**250**:159–65.
- 4 Birkmeyer JD, Lucas FL, Wennberg DE. Potential benefits of regionalizing major surgery in Medicare patients. *Eff Clin Pract* 1999;**2**:277–83.
- 5 Nguyen NT, Paya M, Stevens CM, *et al*. The relationship between hospital volume and outcome in bariatric surgery at academic medical centers. *Ann Surg* 2004;**240**:586–93.
- 6 Pieper D, Mathes T, Neugebauer E, *et al*. State of evidence on the relationship between high-volume hospitals and outcomes in surgery: a systematic review of systematic reviews. *J Am Coll Surg* 2013;**216**:1015–25.
- 7 Trinh QD, Bjartell A, Freedland SJ, *et al*. A systematic review of the volume-outcome relationship for radical prostatectomy. *Eur Urol* 2013;**64**:786–98.
- 8 Hounscome LS, Verne J, McGrath JS, *et al*. Trends in operative caseload and mortality rates after radical cystectomy for bladder cancer in England for 1998–2010. *Eur Urol* 2015;**67**:1056–62.
- 9 Tan H-J, Norton EC, Ye Z, *et al*. Long-term Survival Following Partial vs Radical Nephrectomy Among Older Patients With Early-Stage Kidney Cancer. *JAMA* 2012;**307**:1629–35.

- 1
2
3 10 Kim SP, Thompson RH, Boorjian S a, *et al.* Comparative effectiveness for survival and
4
5 renal function of partial and radical nephrectomy for localized renal tumors: a
6
7 systematic review and meta-analysis. *J Urol* 2012;**188**:51–7.
8
9
10 11 Ferlay J, Soerjomataram I, Ervik M, *et al.* GLOBOCAN 2012 v1.0, Cancer Incidence and
12
13 Mortality Worldwide: IARC CancerBase No. 11. 2013.<http://globocan.iarc.fr> (accessed
14
15 5 Jan 2016).
16
17
18 12 Znaor A, Lortet-Tieulent J, Laversanne M, *et al.* International variations and trends in
19
20 renal cell carcinoma incidence and mortality. *Eur Urol* 2015;**67**:519–30.
21
22
23 13 Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews
24
25 and meta-analyses: the PRISMA statement. *PLoS Med* 2009;**6**:e1000097.
26
27
28 14 Yasunaga H, Yanaihara H, Fuji K, *et al.* Influence of hospital and surgeon volumes on
29
30 operative time, blood loss and perioperative complications in radical nephrectomy. *Int*
31
32 *J Urol* 2008;**15**:688–93.
33
34
35 15 Yap SA, Horovitz D, Alibhai SMH, *et al.* Predictors of early mortality after radical
36
37 nephrectomy with renal vein or inferior vena cava thrombectomy - a population-
38
39 based study. *BJU Int* 2012;**110**:1283–8.
40
41
42
43 16 Awopetu a. I, Moxey P, Hinchliffe RJ, *et al.* Systematic review and meta-analysis of
44
45 the relationship between hospital volume and outcome for lower limb arterial surgery.
46
47 *Br J Surg* 2010;**97**:797–803.
48
49
50 17 Holt PJE, Poloniecki JD, Loftus IM, *et al.* Meta-Analysis and Systematic Review of the
51
52 Relationship between Hospital Volume and Outcome Following Carotid
53
54 Endarterectomy. *Eur J Vasc Endovasc Surg* 2007;**33**:645–51.
55
56
57
58 18 Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? a
59
60

- 1
2
3 systematic review and methodologic critique of the literature. *Ann Intern Med*
4
5 2002;**137**:511–20.
6
7
8 19 Mayer EK, Purkayastha S, Athanasiou T, *et al.* Assessing the quality of the volume-
9
10 outcome relationship in uro-oncology. *BJU Int* 2009;**103**:341–9.
11
12
13 20 StataCorp. Stata Statistical Software: Release 14. 2015.
14
15
16 21 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*
17
18 2002;**21**:1539–58.
19
20
21 22 Higgins JPT, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses.
22
23 *BMJ* 2003;**327**:557–60.
24
25
26 23 Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-
27
28 analyses of controlled trials with binary endpoints. *Stat Med* 2006;**25**:3443–57.
29
30
31 24 Duval S, Tweedie R. A Nonparametric ‘Trim and Fill’ Method of Accounting for
32
33 Publication Bias in Meta-Analysis. *J Am Stat Soc* 2000;**95**:89–98.
34
35
36 25 Hjelle KM, Johannesen TB, Beisland C. Postoperative 30-day Mortality Rates for
37
38 Kidney Cancer Are Dependent on Hospital Surgical Volume: Results from a Norwegian
39
40 Population-based Study. *Eur Urol Focus*;:1–8.
41
42
43 26 Becker A, Bianchi M, Hansen J, *et al.* Benefit in regionalization of care for patients
44
45 treated with nephrectomy: a Nationwide Inpatient Sample. *World J Urol*
46
47 2014;**32**:1511–21.
48
49
50 27 Sun M, Bianchi M, Trinh Q-D, *et al.* Hospital volume is a determinant of postoperative
51
52 complications, blood transfusion and length of stay after radical or partial
53
54 nephrectomy. *J Urol* 2012;**187**:405–10.
55
56
57
58
59
60

- 1
2
3 28 Hanchanale VS, Javlé P. Impact of hospital provider volume on outcome for radical
4 urological cancer surgery in England. *Urol Int* 2010;**85**:11–5.
5
6
7
8 29 Yasunaga H, Yanaihara H, Fuji K, *et al*. Impact of hospital volume on postoperative
9 complications and in-hospital mortality after renal surgery: data from the Japanese
10 Diagnosis Procedure Combination database. *Urology* 2010;**76**:548–52.
11
12
13 30 Mitchell RE, Lee BT, Cookson MS, *et al*. Radical nephrectomy surgical outcomes in the
14 University HealthSystem Consortium data base: impact of hospital case volume,
15 hospital size, and geographic location on 40,000 patients. *Cancer* 2009;**115**:2447–52.
16
17
18 31 Davenport K, Timoney AG, X KF, *et al*. A 3-year review of The British Association of
19 Urological Surgeons Section of Endourology Laparoscopic Nephrectomy Audit. *BJU Int*
20 2006;**97**:333–7.
21
22
23 32 Keoghane SR, Keeley FX, Timoney AG, *et al*. The British Association of Urological
24 Surgeons section of endourology audit of laparoscopic nephrectomy. *BJU Int*
25 2004;**94**:577–81.
26
27
28 33 Taub DA, Miller DC, Cowan JA, *et al*. Impact of surgical volume on mortality and length
29 of stay after nephrectomy. *Urology* 2004;**63**:862–7.
30
31
32 34 Goodney PP, Stukel TA, Lucas FL, *et al*. Hospital volume, length of stay, and
33 readmission rates in high-risk surgery. *Ann Surg* 2003;**238**:161–7.
34
35
36 35 Birkmeyer JD, Siewers AE, Finlayson EVA, *et al*. Hospital volume and surgical mortality
37 in the United States. *N Engl J Med* 2002;**346**:1128–37.
38
39
40 36 Porpiglia F, Mari A, Bertolo R, *et al*. Partial Nephrectomy in Clinical T1b Renal Tumors:
41 Multicenter Comparative Study of Open, Laparoscopic and Robot-assisted Approach
42 (the RECORd Project). *Urology* 2016;**89**:45–51.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 37 Couapel J-P, Bensalah K, Bernhard J-C, *et al.* Is there a volume–outcome relationship
4 for partial nephrectomy? *World J Urol* 2014;**32**:1323–9.
5
6
7
8 38 Monn MF, Bahler CD, Flack CK, *et al.* The impact of hospital volume on postoperative
9 complications following robot-assisted partial nephrectomy. *J Endourol*
10 2014;**28**:1231–6.
11
12
13 39 Abouassaly R, Finelli A, Tomlinson GA, *et al.* Volume-outcome relationships in the
14 treatment of renal tumors. *J Urol* 2012;**187**:1984–8.
15
16
17
18 40 Toren P, Abouassaly R, Timilshina N, *et al.* Results of a national population-based
19 study of outcomes of surgery for renal tumors associated with inferior vena cava
20 thrombus. *Urology* 2013;**82**:572–7.
21
22
23
24 41 Withington JM, Charman SC, Armitage JN, *et al.* Hospital Volume Does Not Influence
25 the Safety of Percutaneous Nephrolithotomy in England: A Population-Based Cohort
26 Study. *J Endourol* 2015;**29**:899–906.
27
28
29
30 42 Lariviere CA, McAteer JP, Huaco JA, *et al.* Outcomes in pediatric surgery by hospital
31 volume: A population-based comparison. *Pediatr Surg Int* 2013;**29**:561–70.
32
33
34
35 43 Eskander A, Merdad M, Irish JC, *et al.* Volume-outcome associations in head and neck
36 cancer treatment: a systematic review and meta-analysis. *Head Neck* 2014;**36**:1820–
37 34.
38
39
40
41 44 Strom JB, Wimmer NJ, Wasfy JH, *et al.* Association between operator procedure
42 volume and patient outcomes in percutaneous coronary intervention: a systematic
43 review and meta-analysis. *Circ Cardiovasc Qual Outcomes* 2014;**7**:560–6.
44
45
46
47
48 45 Hata T, Motoi F, Ishida M, *et al.* Effect of hospital volume on surgical outcomes after
49 pancreaticoduodenectomy. *Ann Surg* 2016;**263**:664–72.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 46 Boogaarts HD, van Amerongen MJ, de Vries J, *et al.* Caseload as a factor for outcome
4
5 in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. *J*
6
7 *Neurosurg* 2014;**120**:605–11.
8
9
10 47 Luft HS, Hunt SS, Maerki SC. The volume-outcome relationship: practice-makes-
11
12 perfect or selective-referral patterns? *Health Serv Res* 1987;**22**:157–82.
13
14
15 48 Corman JM, Penson DF, Hur K, *et al.* Comparison of complications after radical and
16
17 partial nephrectomy: Results from the National Veterans Administration Surgical
18
19 Quality Improvement Program. *BJU Int* 2000;**86**:782–9.
20
21
22 49 Hollenbeck BK, Taub D a, Miller DC, *et al.* Use of nephrectomy at select medical
23
24 centers--a case of follow the crowd? *J Urol* 2006;**175**:670–4.
25
26
27
28 50 Nuttall M, Cathcart P, van der Meulen J, *et al.* A description of radical nephrectomy
29
30 practice and outcomes in England: 1995-2002. *BJU Int* 2005;**96**:58–61.
31
32
33 51 Fedeli U, Novara G, Alba N, *et al.* Trends from 1999 to 2007 in the surgical treatments
34
35 of kidney cancer in Europe: Data from the Veneto Region, Italy. *BJU Int*
36
37 2010;**105**:1255–9.
38
39
40 52 Birkmeyer J, Stukel T, Siewers A, *et al.* Surgeon volume and operative mortality in the
41
42 United States. *N Engl J Med* 2003;**349**:2117–27.
43
44
45 53 Brusselaers N, Mattsson F, Lagergren J. Hospital and surgeon volume in relation to
46
47 long-term survival after oesophagectomy: systematic review and meta-analysis. *Gut*
48
49 2014;**63**:1393–400.
50
51
52 54 Sahni NR, Dalton M, Cutler DM, *et al.* Surgeon specialization and operative mortality
53
54 in United States: retrospective analysis. *BMJ* 2016;**354**:i3571.
55
56
57
58
59
60

- 1
2
3 55 Birkmeyer JD, Sun Y, Wong SL, *et al.* Hospital volume and late survival after cancer
4 surgery. *Ann Surg* 2007;**245**:777–83.
5
6
7
8 56 Gooiker GA, Van Gijn W, Wouters MWJM, *et al.* Systematic review and meta-analysis
9 of the volume-outcome relationship in pancreatic surgery. *Br J Surg* 2011;**98**:485–94.
10
11
12
13 57 Berger DH, Ko CY, Spain DA, *et al.* Society of University Surgeons position statement
14 on the volume-outcome relationship for surgical procedures. *Surgery* 2003;**134**:34–40.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **SUPPORTING INFORMATION CAPTIONS**
4

5 **S1 Appendix.** Preferred Reporting Items for Systematic Reviews and Meta-Analyses
6

7
8 (PRISMA) checklist.
9

10
11
12
13 **S2 Appendix.** Literature search algorithm used in Medline, Embase and the Cochrane Library.
14
15

16
17
18
19 **S3 Appendix.** Results of meta-regression investigating the potential explanatory variables for
20
21 the heterogeneity in the meta-analyses for mortality in **A.** radical nephrectomy and **B.** partial
22
23 nephrectomy.
24
25

26
27
28
29 **S4 Appendix.** List of excluded studies after full-text review and justifications.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig 1. Flow chart of the article selection process.

58x60mm (300 x 300 DPI)






Fig 2. Forest plots displaying the pooled estimates of nephrectomy mortality in HV and LV hospitals for A. radical nephrectomy B. partial nephrectomy C. nephrectomy with venous thrombectomy.

100x105mm (300 x 300 DPI)




Fig 3. Contour-enhanced funnel plot of studies analysing hospital volume-outcome relationship in radical nephrectomy for A. mortality B. complications. Harbord’s modified test for funnel plot asymmetry was not statistically significant for both.

111x160mm (300 x 300 DPI)




Fig 4. Forest plots displaying the pooled estimates of nephrectomy complications in HV and LV hospitals for A. radical nephrectomy B. partial nephrectomy.

101x66mm (300 x 300 DPI)



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	7
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7-8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7-8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7-8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8-9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis).	8-9



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	9-10
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	9-10
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	11
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	11-13
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	11-13
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	14-17
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	14-17
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	14-17
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	14-18
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	19
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	20-22
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	20-23
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	1

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

S2 Appendix. Literature search algorithm for Medline, Embase and the Cochrane Library.

Medline

Nephrectomy Terms:

1. exp Nephrectomy/
2. nephrectom*.mp.
3. (kidney* adj5 (excision* or remov*)).mp.
4. 1 or 2 or 3

Surgeon or Hospital Volume Terms

5. ((physician* or urol* or surg* or operat* or hospital* or procedure*) adj5 (volume* or workload* or caseload* or performance* or number*)).mp.
6. exp Hospitals/
7. exp Surgeons/
8. (volume* or workload* or caseload* or performance*).mp.
9. exp Workload/
10. 6 and 8
11. 7 and 8
12. 6 and 9
13. 7 and 9
14. exp Centralized Hospital Services/
15. centrali*ation.mp.
16. 5 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15

Outcome Terms

17. exp "Outcome Assessment (Health Care)"/
18. exp Patient Outcome Assessment/
19. exp "Outcome and Process Assessment (Health Care)"/
20. outcome.mp.
21. exp Treatment Outcome/
22. exp Mortality/
23. mortalit*.mp.
24. exp Morbidity/
25. morbidit*.mp.
26. exp "Length of Stay"/
27. length of stay.mp.
28. ((duration or length or period) adj5 (stay or hospital*)).mp.
29. exp Survival/
30. survival.mp.
31. exp Patient Readmission/
32. readmission.mp.
33. exp Postoperative Complications/
34. complication*.mp.
35. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
36. 4 and 16 and 35

Embase

Nephrectomy Terms:

1. exp Nephrectomy/
2. exp Partial nephrectomy/
3. exp "Patient history of nephrectomy"/
4. nephrectom*.mp.
5. (kidney* adj5 (excision* or remov*)).mp.
6. 1 or 2 or 3 or 4 or 5

Surgeon or Hospital Volume Terms

7. ((physician* or urol* or surg* or operat* or hospital* or procedure*) adj5 (volume* or workload* or caseload* or performance* or number*)).mp.
8. exp Hospital/

9. exp Surgeon/
10. (volume* or workload* or caseload* or performance*).mp.
11. exp Workload/
12. 8 and 10
13. 9 and 10
14. 8 and 11
15. 9 and 11
16. exp Centralization/
17. centrali*ation.mp.
18. 7 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17

Outcome Terms

19. exp Outcome Assessment/
20. exp Treatment Outcome/
21. outcome.mp.
22. exp Mortality/
23. mortalit*.mp.
24. exp Morbidity/
25. morbidit*.mp.
26. exp "Length of Stay"/
27. length of stay.mp.
28. ((duration or length or period) adj5 (stay or hospital*)).mp.
29. exp Survival/
30. survival.mp.
31. exp Hospital readmission/
32. readmission.mp.
33. exp Postoperative Complications/
34. complication*.mp.
35. 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
36. 6 and 18 and 35

Cochrane Library

Nephrectomy Terms:

1. exp Nephrectomy/
2. nephrectom*
3. kidney* near (excision* or remov*)
4. 1 or 2 or 3

Surgeon or Hospital Volume Terms

5. (physician* or urol* or surg* or operat* or hospital* or procedure*) near (volume* or workload* or caseload* or performance* or number*)
6. exp Hospitals/
7. exp Surgeons/
8. volume* or workload* or caseload* or performance*
9. exp Workload/
10. 6 and 8
11. 7 and 8
12. 6 and 9
13. 7 and 9
14. exp Centralized Hospital Services/
15. centrali*ation
16. 5 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15

Outcome Terms

17. exp "Outcome Assessment (Health Care)"/
18. exp Patient Outcome Assessment/
19. exp "Outcome and Process Assessment (Health Care)"/
20. outcome
21. exp Treatment Outcome/
22. exp Mortality/

- 1
- 2
- 3 23. mortalit*
- 4 24. exp Morbidity/
- 5 25. morbidit*
- 6 26. exp "Length of Stay"/
- 7 27. length of stay
- 8 28. (duration or length or period) near (stay or hospital*)
- 9 29. exp Survival/
- 10 30. survival
- 11 31. exp Patient Readmission/
- 12 32. readmission
- 13 33. exp Postoperative Complications/
- 14 34. complication*
- 15 35. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
- 16 36. 4 and 16 and 35
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

S3 Appendix. Results of meta-regression investigating the heterogeneity in the meta-analyses for mortality and its potential explanatory variables in **A.** radical nephrectomy and **B.** partial nephrectomy.

A.

Explanatory Variable	Regression Coefficient	95% Confidence Interval	p Value
Study year	0.96	0.88, 1.04	0.24
Country of Study			
England	1.46	0.70-3.02	0.24
Japan	0.76	0.28-2.04	0.50
Norway	0.42	0.10-1.76	0.18
USA	1.06	0.51, 2.21	0.85
Data type			
Administrative	1.36	0.71, 2.61	0.28
Clinical	0.74	0.38, 1.32	0.28
Number of patients	1.00	1.00, 1.00	0.45
Number of hospitals	1.00	1.00, 1.00	0.14
Patient age (mean)	0.92	0.70, 1.19	0.36
Patient gender (% of male)	0.96	0.88, 1.05	0.25
Threshold for HV hospitals	0.99	0.99, 1.00	0.01

B.

Explanatory Variable	Regression Coefficient	95% Confidence Interval	p Value
Study year	0.96	0.80, 1.14	0.51
Country of Study			
England	1.42	0.46, 4.27	0.40
Japan	1.19	0.67, 2.13	0.41
USA	0.80	0.51, 1.26	0.22
Data type			
Administrative	1.09	0.61, 1.97	0.66
Clinical	0.91	0.51, 1.65	0.66
Number of patients	1.00	1.00, 1.00	0.26
Number of hospitals	1.00	0.99, 1.00	0.80
Patient age (mean)	1.04	0.97, 1.11	0.16
Patient gender (% of male)	0.99	0.80, 1.23	0.87
Threshold for HV hospitals	1.00	0.93, 1.07	0.83

S4 Appendix. List of excluded studies after full-text review and justifications.

Reference	Justification
1. Finlayson EVA, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery: a national study. <i>Arch Surg.</i> 2003;138(7):721-726.	Overlapping studied period. Eliminated as per rule 4.
2. Gilbert SM, Dunn RL, Miller DC, Daignault S, Ye Z, Hollenbeck BK. Mortality After Urologic Cancer Surgery: Impact of Non-index Case Volume. <i>Urology.</i> 2008;71(5):906-910.	Overlapping studied period. Eliminated as per rule 2.
3. Joudi FN, Allareddy V, Kane CJ, Konety BR. Analysis of complications following partial and total nephrectomy for renal cancer in a population based sample. <i>J Urol.</i> 2007;177(5):1709-1714.	Overlapping studied period. Eliminated as per rule 2.
4. Joudi FN, Konety BR. The impact of provider volume on outcomes from urological cancer therapy. <i>J Urol.</i> 2005;174(2):432-438.	Review
5. Joudi FN, Konety BR. The volume/outcome relationship in urologic cancer surgery. <i>Support Cancer Ther.</i> 2004;2(1):42-46.	Review
6. Killen SD, O'Sullivan MJ, Coffey JC, Kirwan WO RH. Provider volume and outcomes for oncological procedures. <i>Br J Surg.</i> 2005;92:389-402.	Review
7. Konety BR, Allareddy V, Modak S, Smith B. Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better? <i>J Clin Oncol.</i> 2006;24(13):2006-2012.	Overlapping studied period. Eliminated as per rule 2.
8. Mayer EK, Purkayastha S, Athanasiou T, Darzi A, Vale JA. Assessing the quality of the volume-outcome relationship in uro-oncology. <i>BJU Int.</i> 2009;103(3):341-349.	Review
9. Nuttall M, Vandermeulen J, Phillips N, et al. a Systematic Review and Critique of the Literature Relating Hospital or Surgeon Volume To Health Outcomes for 3 Urological Cancer Procedures. <i>J Urol.</i> 2004;172(6):2145-2152.	Review
10. Penson DF. Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better? <i>Urol Oncol.</i> 2006;24(5):460.	Commentary
11. Peyronnet B, Couapel J-P, Patard J-J, Bensalah K. Relationship between surgical volume and outcomes in nephron-sparing surgery. <i>Curr Opin Urol.</i> 2014;24(5):453-458.	Review
12. Pieper D, Mathes T, Neugebauer E, Eikermann M. State of evidence on the relationship between high-volume hospitals and outcomes in surgery: a systematic review of systematic reviews. <i>J Am Coll Surg.</i> 2013;216(5):1015-1025.	Review
13. Sugihara T, Yasunaga H, Horiguchi H, et al. Performance comparisons in major uro-oncological surgeries between the USA and Japan. <i>Int J Urol.</i> 2014;21(11):1145-1150.	Volume-outcome relationship not described
14. Trinh QD, Schmitges J, Sun M, et al. Does partial nephrectomy at an academic institution result in better outcomes? <i>World J Urol.</i> 2012;30(4):505-510.	Overlapping studied period. Eliminated as per rule 2.
15. Wang HH, Tejwani R, Zhang H, Wiener JS, Routh JC. Hospital Surgical Volume and Associated Postoperative Complications of Pediatric Urological Surgery in the United States. <i>J Urol.</i> 2015;194(2):506-511.	Paediatric cohort
16. Fernando A, Fowler S, O'Brien T, et al. Nephron-sparing surgery across a nation - Outcomes from the British Association of Urological Surgeons 2012 national partial nephrectomy audit. <i>BJU Int.</i> 2016;117(6):874-82.	Volume-outcome relationship not described
17. Tinay I, Gelpi-Hammerschmidt F, Leow JJ, et al. Trends in utilisation, perioperative outcomes, and costs of nephroureterectomies in the management of upper tract urothelial carcinoma: A 10-year population-based analysis. <i>BJU Int.</i> 2016;117(6):954-60.	Volume-outcome relationship in nephroureterectomy only

BMJ Open

Influence of Hospital Volume on Nephrectomy Mortality and Complications: A Systematic Review and Meta-Analysis Stratified by Surgical Type

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016833.R1
Article Type:	Research
Date Submitted by the Author:	22-May-2017
Complete List of Authors:	Hsu, Ray; University of Cambridge, Academic Urology Group, Department of Surgery; Cambridge University Hospitals NHS Foundation Trust, Department of Urology Salika, Theodosia; University College London, Department of Epidemiology & Public Health, Health Behaviour Research Centre Maw, Jonathan; Cambridge University Hospitals NHS Foundation Trust, Department of Urology Lyratzopoulos, Georgios ; University College London, Department of Epidemiology & Public Health, Health Behaviour Research Centre Gnanapragasam, Vincent; University of Cambridge, Academic Urology Group, Department of Surgery; Cambridge University Hospitals NHS Foundation Trust, Department of Urology Armitage, James; Cambridge University Hospitals NHS Foundation Trust, Department of Urology
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Urology, Surgery
Keywords:	Hospital Volume, Nephrectomy, Nephrectomy Mortality, Nephrectomy Complications, Kidney & urinary tract disorders < UROLOGY, Urological tumours < UROLOGY

SCHOLARONE™
Manuscripts

1
2
3 **INFLUENCE OF HOSPITAL VOLUME ON NEPHRECTOMY MORTALITY AND COMPLICATIONS:**
4
5 **A SYSTEMATIC REVIEW AND META-ANALYSIS STRATIFIED BY SURGICAL TYPE**
6
7

8
9
10 Ray CJ Hsu,^{1,2} Theodosia Salika,³ Jonathan Maw,² Georgios Lyratzopoulos,³ Vincent J
11
12 Gnanapragasam,^{1,2,†} James N Armitage,^{2,†}
13
14

15
16
17 ¹Academic Urology Group, Department of Surgery, University of Cambridge, Cambridge
18
19 Biomedical Campus, Hills Road, Cambridge, UK, CB2 0QQ
20

21
22 ²Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS
23
24 Foundation Trust, Hills Road, Cambridge, UK, CB2 0QQ
25

26
27 ³Health Behaviour Research Centre, Department of Epidemiology and Public Health,
28
29 University College London, 1-19 Torrington Place, London, UK, WC1E 6BT
30

31 [†]Joint senior authors.
32
33

34
35
36 Corresponding author: Ray CJ Hsu
37

38 E-mail address: rch72@cam.ac.uk
39
40

41
42
43 Word count: 3,801
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives

The provision of complex surgery is increasingly centralised to high volume specialist hospitals. Evidence to support nephrectomy centralisation however has been inconsistent. We conducted a systematic review and meta-analysis to determine the association between hospital case volumes and perioperative outcomes in radical nephrectomy, partial nephrectomy and nephrectomy with venous thrombectomy.

Methods

Medline, Embase and the Cochrane Library were searched for relevant studies published between 1990 and 2016. Pooled effect estimates for nephrectomy mortality and complications were calculated for each nephrectomy type using the DerSimonian and Laird random-effects model. Sensitivity analyses were performed to examine the effects of heterogeneity on the pooled effect estimates by excluding studies with the heaviest weighting, lowest methodological score, and most likely to introduce bias from misclassification of standardised hospital volume.

Results

Some 226,372 patients from sixteen publications were included in our review and meta-analysis. Considerable between-study heterogeneity was noted and only a few reported volume-outcome relationships specifically in partial nephrectomy or nephrectomy with venous thrombectomy.

1
2
3 High volume hospitals were correlated with a 26% and 52% reduction in mortality for radical
4
5 nephrectomy (OR 0.74, 95% CI 0.61-0.90, $p<0.01$) and nephrectomy with venous
6
7 thrombectomy (OR 0.48, 95% CI 0.29-0.81, $p<0.01$) respectively. In addition, radical
8
9 nephrectomy in high volume hospitals was associated with an 18% reduction in
10
11 complications (OR 0.82, 95% CI 0.73-0.92, $p<0.01$). No significant volume-outcome
12
13 relationship in mortality (OR 0.84, 95% CI 0.31-2.26, $p=0.73$) or complications (OR 0.85, 95%
14
15 CI 0.55-1.30, $p=0.44$) was observed for partial nephrectomy.
16
17
18
19
20
21

22 **Conclusions**

23
24 Our findings suggest that patients undergoing radical nephrectomy have improved
25
26 outcomes when treated by high volume hospitals. Evidence of this in partial nephrectomy
27
28 and nephrectomy with venous thrombectomy is however not yet clear and could be
29
30 secondary to the low number of studies included and the small patient number in our
31
32 analyses. Further investigation is warranted to establish the full potential of nephrectomy
33
34 centralisation particularly as existing evidence is of low quality with significant heterogeneity.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STRENGTH & LIMITATIONS OF THIS STUDY

- This is a contemporary systematic review and meta-analysis of the associations between hospital case volumes and nephrectomy outcomes.
- Sixteen primary studies, which is four folds greater in number than previous meta-analyses, were used to synthesised the pooled effect estimates for nephrectomy mortality and complications.
- To the best of our knowledge, this is the first study to date to stratify analyses based on nephrectomy type to account for differences in technical complexity and rates of adverse outcomes.
- Current evidence in nephrectomy outcome-volume relationship is of low quality and considerable heterogeneity exists between studies in design, type of data used, outcomes measured and statistical methodologies.
- Our study highlights the limitations in existing evidence and suggests questions that should be addressed in future research.

INTRODUCTION

In recent years, there has been an emerging trend for the centralisation of complex operations in healthcare systems around the world [1–3]. This shift is supported by the growing research and evidence suggesting that hospitals and surgeons with high case loads have better patient outcomes [4–8]. Proponents argue that centralisation allows more effective use of clinical expertise and specialist equipment, and the increased exposure improves surgical skills and provides better training opportunities. Centralisation can also facilitate quicker adoption of care pathways, such as enhanced recovery, and may have more long-term financial sustainability for hospitals. However, surgical centralisation requires further travel distance and limits patient choice when many would prefer to undergo surgery locally even if greater mortality risks are taken into consideration [9]. Differences in disease biology, surgical complexity and rate of adverse outcomes may also limit the perceived benefits of centralisation. Such a health service model may therefore not be appropriate for all conditions and operations.

Renal cancer accounts for over 2% of all new cancer diagnoses worldwide affecting more than 330,000 individuals annually [10]. Widespread use of cross-sectional imaging and increasing prevalence of obesity have contributed to a rising renal cancer incidence in many countries [11–13]. Despite recent developments in systemic therapies, nephrectomy is often considered the only potentially curative treatment for renal cancer, and the number of nephrectomies being performed is likely to increase as a result. It is therefore critical that health service providers understand the effects that organisational changes may have on patient outcomes. While there has been an expansion of volume-outcome research, no consensus has so far been reached on the efficacy of centralising nephrectomy, and many

1
2
3 uncertainties remain about its potential benefits particularly as radical and partial
4
5 nephrectomy carry different surgical complexities and outcomes [14,15]. We present a
6
7 contemporary systematic review and meta-analysis of the published literature on the
8
9 association between hospital case volumes and perioperative outcomes stratified by
10
11 nephrectomy types. We hypothesise that outcomes significantly improve with higher
12
13 nephrectomy case volumes.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Search criteria & data extraction

The systematic review and meta-analysis was reported in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Appendix 1) [16]. Medical subject heading (MeSH) terms and key words for nephrectomy, case volume and outcomes were used in Medline, Embase and the Cochrane Library to search for relevant studies published between January 1990 and December 2016 (Appendix 2). Studies published prior to 1990 were not considered as recent medical and surgical advancements would have limited their applicability to the modern healthcare system. Only studies published in English were considered as the risk of potential language bias associated with this exclusion generally has little effect on summary effect estimates [17]. References were searched manually for additional relevant studies.

We included studies that presented original data in full-texts on adult nephrectomy outcomes across two or more hospital case volume categories. Abstracts, case reports, and review articles were excluded. No restriction was set on the study design and both prospective and retrospective studies were considered. Only those describing the volume-outcome relationships in radical nephrectomy with or without venous thrombectomy and/or partial nephrectomy were eligible. Paediatric cohorts were excluded as were articles comprised solely of nephroureterectomy or nephrectomy for non-oncological indications. Restriction on the reported outcomes was only applied at the end stage of the search to enable assessment of the current published evidence. Only studies reporting nephrectomy mortality and complications were included in the final analysis.

1
2
3 Two investigators (R.C.J.H and J.M.) independently reviewed all studies for inclusion, data
4
5 extraction and methodological quality. Any disagreement between the two reviewers was
6
7 resolved by discussion and consultation with a third reviewer (J.N.A.). Where only rates of
8
9 outcomes were presented, these were applied to the case number to give the number of
10
11 events, within the error of the published results. Study authors were contacted for further
12
13 clarification if specific rates of outcomes and case numbers were not published [18,19].
14
15

16
17
18
19 As the cut-off values for hospital case volume categories differed among studies, we used
20
21 the approach adopted by similar previous meta-analyses by dichotomising the volume
22
23 groups presented by each study into low volume (LV) and high volume (HV) when the article
24
25 presented an even number of volume groupings [20,21]. If a study presented an odd
26
27 number of volume groups, the middle group was considered as LV.
28
29

30
31
32
33 Methodological quality and potential risk of bias were scored using a ten-domain system
34
35 designed to measure the degree in which the study is likely to reveal generalizable
36
37 conclusion about the magnitude and nature of the volume-outcome relationship [22,23].
38
39 Each domain provides a score between zero and three with a total maximum of 18,
40
41 suggesting a well-designed study. The parameters included the representativeness of the
42
43 sample, the number of hospitals analysed, the samples size, the number of adverse events
44
45 recorded, the appropriateness of patient selection, the number of volume categories
46
47 examined, the number of outcomes measured, the degree of risk adjustment performed,
48
49 whether hospital and surgeon case volumes were analysed in conjunction, and whether
50
51 clinical processes of care were measured.
52
53
54
55
56
57
58
59
60

1
2
3 If studies extracted data from the same source with overlaps in the study periods, we
4
5 employed the following rules to avoid duplicating populations: 1) studies with identical
6
7 patient cohort but examining different outcomes were considered and analysed separately;
8
9
10 2) studies that derived data from older datasets were excluded in favour of the more
11
12 contemporary cohort; 3) if the above rules were not applicable, studies with the lower
13
14 methodological quality scores were excluded; 4) where quality scores were equal, the study
15
16 covering the longest period was included.
17
18
19
20

21 **Quantitative data synthesis**

22
23 All statistical analyses were performed using Stata 14 [24]. Nephrectomy types were
24
25 categorised into radical nephrectomy, partial nephrectomy and nephrectomy with venous
26
27 thrombectomy and analysed separately. Studies involving multiple types of nephrectomies
28
29 were analysed based on the aforementioned groups, but if this was not feasible, they were
30
31 categorised as radical nephrectomy. With the assumption that a distribution of effects exists
32
33 amongst studies, all pooled effect size were calculated using the DerSimonian and Laird
34
35 random-effects model, which provided more conservative estimates compared to fixed-
36
37 effect model. Odds ratio (OR) and 95% confidence interval (CI) were calculated and
38
39 presented for each outcome measure using LV groups as the reference.
40
41
42
43
44
45
46
47

48 When the meta-analysis demonstrated significantly better outcomes in HV hospitals, we
49
50 quantified the clinical effectiveness of centralisation by calculating the numbers needed to
51
52 treat, or in our case numbers needed to centralise (NNC). NNC represents the number of
53
54 cases that will need to be centralised from LV hospitals and treated by HV hospitals in order
55
56 to prevent one adverse event.
57
58
59
60

Heterogeneity

As the DerSimonian and Laird model would have only accounted for some between-study heterogeneity, we further quantified heterogeneity by calculating I^2 statistic. I^2 provides an easily understood number, which describes the proportion of total variation in estimates that is due to heterogeneity rather than chance [25]. Values of 25% or lower denote low heterogeneity and values of 75% or greater denote considerable heterogeneity [26]. Meta-regression was performed to explore the influence of potential explanatory variables on heterogeneity including each study's publication year, country, data source, number of patients and their demographics, number of hospitals, and threshold for HV hospitals.

Publication bias

Funnel plots were generated to investigate potential publication bias, and were enhanced to include contours that divide the funnel into statistically significant and non-significant areas. Funnel plot symmetry suggests low probability of publication bias and Harbord's modified test was used to test for asymmetry [27]. Harbord's test reduces false positive rates when applied to binary outcome data, especially when there is low between-study heterogeneity. Trim and fill method was also performed to account for publication bias by adjusting the meta-analysis to incorporate the theoretically missing studies [28].

Sensitivity analysis

To examine specific studies' effects on pooled effect size, sensitivity analyses were performed by excluding individual studies and repeating the meta-analyses. We examined the effects of studies with the heaviest weighting and studies with the lowest

1
2
3 methodological quality score. As there is currently no consensus on what nephrectomy case
4
5 volume is necessary to be considered as HV, we repeated our analyses by excluding studies
6
7 whose standardised HV categories overlapped most significantly with the standardised LV
8
9 categories in other studies to account for potential bias of misclassifying volume categories
10
11 in our dichotomy.
12
13

14
15
16
17 As secondary analyses, we additionally repeated the meta-analysis three further times with
18
19 different methods of dichotomising the volume groups to examine whether our initial
20
21 estimates would remain consistent. The methods of dichotomising were 1) lowest volume
22
23 categories and all others 2) even dichotomy and when studies present an odd number of
24
25 volume categories, the middle group was considered as HV 3) highest volume categories and
26
27 all others.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Study selection & characteristics

From the 5,680 articles initially identified, 16 were included in the systematic review containing 226,372 patients from six countries (Figure 1). For the meta-analysis, eleven studies with 201,506 patients examining radical nephrectomy were included while four studies of 23,617 patients and two studies of 1,249 patients examining partial nephrectomy and nephrectomy with venous thrombectomy were included respectively. Publication year ranged from 2002 to 2016, while cohort periods covered from 1993 to 2013.

Tables 1 summarises the characteristics of the included studies. Variations were observed in study designs including source of data and outcomes measured. Out of a maximum possible score of 18, the median quality score from the included studies was 9 (interquartile range 8 – 9) with the majority of the studies failing to adequately address potential confounders including measuring the appropriateness of patient selection, adjusting for case-mix variations and accounting for differences in clinical risks and processes of care (Appendix 3). Variable thresholds for HV hospitals were noted across the included studies.

Table 1. Characteristics and methodological summary of studies.

Reference	Study Characteristics								Outcomes Measured						Case Mix	Quality Score (18)
	Year	Country	Period	Data Type	No. of Patients	No. of Hospitals	Low ^a	High ^a	Mortality	Complications (breakdowns)	Transfusion	LOS	Conversions	Others		
Radical Nephrectomy																
Hjelle[29]	2016	Norway	2008-2013	Admin	3,273	40	20	40	30-day	-	-	-	+	-	Demographics, tumour stage, nephrectomy type	8
Becker[30]/ Sun[31] ^b	2014 / 2012	USA	1998-2007	Admin	48,172	N/S	5	16	In-hospital	+ (17 events inc haemorrhage, cardiac arrest, infection, wound disruption, seroma, pneumothorax, VTE etc)	+	+	-	-	Demographics, co-morbidity, nephrectomy type, laparoscopy, payer/hospital type	9
Hanchanale[32]	2010	England	1998-2005	Admin	20,672	1,181	14	35	In-hospital	-	-	+	-	-	Demographics	9
Yasunaga[33]	2010	Japan	2006-2007	Admin	7,988	646	26	65	In-hospital	+ (11 events inc surgical site infection, UTI, VTE, sepsis, ileus, stroke, cardiac events, renal, failure, peritonitis etc)	-	-	-	-	Demographics, co-morbidity, laparoscopy, hospital type, tumour location	9
Mitchell[34]	2009	USA	2003-2007	Clinical	42,988	134	99/4.5yr	500/4.5yr	In-hospital	+ (not specified)	-	+	-	ICU admission	None	9
Yasunaga[18]	2008	Japan	2006-2007	Clinical	1,704	461	9	40	In-hospital	+ (wound infection, pneumonia, ileus, renal dysfunction, others)	-	-	-	OT, EBL	Demographics, co-morbidity, laparoscopy, tumour stage & location	11
Davenport[35]	2005	England	2004	Clinical	598	48	<1/mo	>1/mo	N/S	+ (12 events inc bleeding, bowel injury, GI bleed, renal failure, pneumothorax, VTE, MI, splenic injury etc)	+	-	+	OT	None	4
Keoghane[36]	2004	England	2001-2002	Clinical	263	25	5	6	-	+ (16 events inc renal failure, sepsis, wound infection, bowel injury, incisional hernia, perihaptic collection etc)	-	-	+	-	None	3
Taub[37]	2004	USA	1993-1997	Admin	16,858	962	14	34	In-hospital	-	-	+	-	-	Demographics, co-morbidity, admission acuity	9
Birkmeyer[38]	2002	USA	1994-1999	Admin	58,990	3,292	6	33	30-day or In-hospital	-	-	-	-	-	Demographics, co-morbidity, admission acuity	7
Partial Nephrectomy																
Couapel[39]	2014	France	2010	Clinical	570	53	4/7mo	19/7mo	N/S	+ (medical and surgical events, not further specified)	-	+	+	OT, EBL, Totalisation, +ve margin	N/S	8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Monn[40]	2014	USA	2009-2011	Admin	17,583	322	13	35	-	+ (organ based complications not further specified, pain, seroma, shock, haematoma, hypotension, VTE, pneumothorax)	+	+	-	Hospital cost	Demographics, co-morbidity, payer, region, hospital type	9
Abouassaly[41]	2012	Canada	1998-2008	Admin	4,292	181	146/10yr	797/10yr	In-hospital	+ (not specified)	-	-	-	-	Demographics, co-morbidity, region	12
Taub[37]	2004	USA	1993-1997	Admin	1,172	962	14	34	In-hospital	-	-	+	-	-	Demographics, co-morbidity, admission acuity	9
Nephrectomy with Venous Thrombectomy																
Toren[42]	2013	Canada	1998-2008	Admin	816	120	N/S	N/S	In-hospital	+ (40 medical and surgical events inc MI, CHF, PE, infection, organ injury, pneumothorax etc)	+	-	-	-	Demographics, co-morbidity, region	11
Yap[19]	2012	Canada	1995-2004	Admin	433	N/S	2/10yr	8/10yr	30-day	-	-	-	-	-	Demographics	11

^aLow, cut-off value for lowest volume group; high, cut-off value for highest-volume group. Volume units are cases per year unless specified. ^bBecker and Sun were equal in the data source used, outcomes evaluated, periods covered and quality scores, but employed different analyses to evaluate the benefit of regionalisation and volume-outcome relationship in nephrectomy [30,31]. We therefore treated them as one single cohort, with no duplicates in our analysis. Admin: Administrative. N/S: Not specified. VTE: venous thromboembolism. MI: Myocardial infarction. CHF: Congestive heart failure. PE: Pulmonary embolism. UTI: Urinary tract infection. GI: Gastrointestinal. OT: Operating time. EBL: Estimated blood loss. ICU: Intensive care unit.

Mortality and Hospital Volumes

Post-operative mortality, defined as in-patient or 30-day, was the most frequently examined outcome, reported in fourteen studies. Ten studies reported mortality in radical nephrectomy [18,29–35,37,38], three in partial nephrectomy [37,39,41] and two in nephrectomy with venous thrombectomy [19,42]. The overall mortality was 1.59% (range 0.20-7.2) with mortality rates in HV and LV hospitals being 1.47% and 1.68% respectively.

Radical Nephrectomy

Meta-analysis demonstrated that patients who underwent radical nephrectomy in HV hospitals had a 26% reduction (OR 0.74, 95% CI 0.61-0.90, $p < 0.01$) in post-operative mortality, corresponding to a NNC of 234 (Figure 2A). Significant heterogeneity was observed (I^2 75.0%, $p < 0.01$). Meta-regression was performed to investigate the potential explanatory variables for heterogeneity, and only differences in the threshold values for HV hospitals were shown to be a significant contributor (Appendix 4A). Subgroup analysis of the three studies examining exclusively radical nephrectomies demonstrated a more pronounced reduction in post-operative mortality favouring HV hospitals (OR 0.62, 95% CI 0.53-0.71, $p < 0.01$) [18,34,37]. This corresponded to a lower NNC of 166 with little residual heterogeneity (I^2 0.0 %, $p = 0.40$). The overall funnel plot was visually asymmetrical particularly missing studies with effect estimates favouring LV hospitals (Figure 3). However, the Harbord's modified test did not show significant asymmetry ($p = 0.40$) and "trim and fill" method did not change the initial estimate, indicating no clear evidence of publication bias. In sensitivity analyses, exclusion of the most heavily weighted study led to a similar pooled-effect estimate (OR 0.70, 95% CI 0.55-0.88, $p < 0.01$) [38]. Exclusion of the study with the lowest quality score also did not significantly alter our result (OR 0.74, 95% CI 0.61-0.91,

1
2
3 p<0.01) [35]. To examine the potential bias introduced by misclassification of hospital
4
5 volume, two cohorts were excluded [30,31,35]. This did not substantially change our pooled-
6
7 effect estimate either (OR 0.73, 95% CI 0.58-0.93, p=0.01). Overall, radical nephrectomies in
8
9 HV hospitals appeared to have significantly lower mortality.
10
11

12 13 14 15 *Partial Nephrectomy*

16
17 Meta-analysis showed that partial nephrectomy patients operated in HV hospitals had a 16%
18
19 reduction in post-operative mortality but this was not statistically significant (OR 0.84, 95%
20
21 CI 0.31-2.26, p=0.73) (Figure 2B). Moderate but non-significant heterogeneity was noted (I^2
22
23 36.84 %, p=0.21). Sensitivity analyses removing studies with the heaviest weighting [41] or
24
25 most likely to introduce misclassification bias of exposure [39] demonstrated reduced
26
27 mortality favouring HV hospitals, but these remained non-significant.
28
29
30
31

32 33 34 *Nephrectomy with Venous Thrombectomy*

35
36 Patients who underwent nephrectomy with venous thrombectomy in HV hospitals had a
37
38 52% reduction (OR 0.48, 95% CI 0.29-0.81, p<0.01) in short-term mortality compared to LV
39
40 hospitals (Figure 2C). This corresponded to a NNC of 25 with low heterogeneity (I^2 0.0 %,
41
42 p=0.50). Due to the small number of studies reporting this outcome, further testing of
43
44 heterogeneity and publication bias was not expected to generate meaningful results and this
45
46 was not attempted.
47
48
49

50 51 52 **Complications and Hospital Volumes**

53
54
55 Complication was the second most frequently investigated outcome, reported in eleven
56
57 studies. Events considered as a complication differed among studies (Table 1). Seven studies
58
59
60

1
2
3 reported complications in radical nephrectomy [18,30,31,33–36] and three in partial
4
5 nephrectomy [39–41]. Only one study examined volume-outcome relationship in
6
7 nephrectomy with venous thrombectomy and meta-analysis was therefore not appropriate
8
9 [42]. The overall complication rate was 16.26% (range 7.4-78). HV hospitals had complication
10
11 rates of 15.00% compared to 17.51% in LV hospitals.
12
13

14 15 16 17 *Radical Nephrectomy*

18
19 Meta-analysis showed an 18% reduction (OR 0.82, 95% CI 0.73-0.92, $p < 0.01$) in nephrectomy
20
21 complications in HV centres, corresponding to a NNC of 38 (Figure 4A). Significant
22
23 heterogeneity was noted (I^2 76.25%, $p < 0.01$), but none of the factors examined in meta-
24
25 regression significantly contributed to this (Appendix 4B). Sensitivity analyses by removing
26
27 studies with the lowest quality [36] or most likely to introduce misclassification bias of
28
29 exposure [35,36] did not significantly alter our initial result. Excluding study with the
30
31 heaviest weighting however led to a loss of significance in the pooled-effect estimate, which
32
33 however still demonstrated a 11% reduction in complications in HV hospitals (OR 0.89, 95%
34
35 CI 0.74-1.08, $p = 0.24$). Overall, radical nephrectomies performed in HV hospitals appeared to
36
37 have significantly lower complications compared to LV hospitals.
38
39
40
41
42
43
44

45 46 *Partial Nephrectomy*

47
48 Partial nephrectomy patients operated in HV hospitals had a 15% reduction in complications,
49
50 but this was not statistically significant (OR 0.85, 95% CI 0.55-1.30, $p = 0.44$) (Figure 4B).
51
52 Significant heterogeneity was noted (I^2 94.80%, $p < 0.01$). Sensitivity analysis by removing
53
54 studies with the heaviest weighting [40] or most likely to introduce misclassification bias of
55
56 hospital volume [39] did not result in significance.
57
58
59
60

Secondary analyses using different methods for dichotomising HV and LV

As there is no consensus on what constituted HV hospitals in current evidence, simple dichotomy of volume groups may introduce inherent bias to the estimates. Yet no recommendation on how best to proceed in volume-outcome analysis presently exists.

In our secondary analyses, we consistently observed significantly lower risks of mortality for both radical nephrectomy and nephrectomy with venous thrombectomy in HV hospitals regardless how volumes were dichotomised (Table 2). The magnitudes of risk reductions were more pronounced when higher thresholds for HV hospitals were considered particularly for radical nephrectomy mortality. Partial nephrectomy mortality however continued to demonstrate no significant association to volume even when dichotomies were comparing the highest volume groups to all others.

Risks of radical nephrectomy complications remained significantly reduced in HV hospitals when the dichotomy threshold for HV hospitals was increased, but the significance was lost when the thresholds were lowered. Association between hospital volumes and partial nephrectomy complications remained insignificant regardless of how HV was defined in our dichotomy.

Table 2: Results of meta-analysis by using different methods of dichotomising volume groups.

	Lowest volume group vs. all others	Even dichotomy, middle group as HV	Even dichotomy, middle group as LV (Primary analysis)	Highest volume group vs. all others
Mortality				
Radical Nephrectomy	OR: 0.82 95%CI 0.71-0.94 p=0.01	OR: 0.83 95%CI 0.72-0.95 p<0.01	OR: 0.74 95%CI 0.61-0.90 p<0.01	OR: 0.72 95%CI 0.61-0.85 p<0.01
Partial Nephrectomy	OR: 0.48 95%CI 0.18-1.31 p=0.15	OR: 0.67 95%CI 0.17-2.75 p=0.58	OR: 0.84 95%CI 0.31-2.26 p=0.73	OR: 0.93 95%CI 0.31-2.77 p=0.90
Nephrectomy with Venous Thrombectomy	OR: 0.59 95%CI 0.35-0.99 p=0.045	OR: 0.46 95%CI 0.27-0.80 p<0.01	OR: 0.48 95%CI 0.29-0.81 p=0.01	OR: 0.48 95%CI 0.25-0.92 p=0.03
Complications				
Radical Nephrectomy	OR: 0.89 95%CI 0.78-1.01 p=0.07	OR: 0.84 95%CI 0.68-1.05 p=0.13	OR: 0.82 95%CI 0.73-0.92 p<0.01	OR: 0.82 95%CI 0.73-0.92 p<0.01
Partial Nephrectomy	OR: 0.82 95%CI 0.55-1.41 p=0.60	OR: 0.80 95%CI 0.47-1.36 p=0.40	OR: 0.85 95%CI 0.55-1.30 p=0.44	OR: 0.81 95%CI 0.53-1.24 p=0.33

DISCUSSION

Evidence on volume-outcome relationships in complex diseases and procedures has increased substantially in recent years. Many operations have been shown to have improved outcomes in HV centres, but this may not be uniform across all surgeries and benefits have not been associated with volume in percutaneous nephrolithotomy or appendicectomy [43–48]. This meta-analysis provides a contemporary review of the effects of centralisation in nephrectomy outcomes. It reveals significant inverse associations between hospital case volumes for short-term mortality and complications for radical nephrectomy, but evidence of these for partial nephrectomy and nephrectomy with venous thrombectomy remains less compelling.

Considered individually, all but three studies in our review reported lack of associations between hospital volume and nephrectomy mortality [29,37,38]. However, such associations in favour of HV hospitals were apparent when considering the totality of the evidence particularly in radical nephrectomy and venous thrombectomy. This finding is consistent with the only other meta-analysis on nephrectomy volume-outcome relationship published in 2009 but includes four-fold greater number of studies [23]. Our meta-analysis demonstrates that the mortality benefit seen in radical nephrectomy may be relatively small requiring centralisation of 234 patients in order to avoid one death. However, the NNC decreased considerably to 166 in our sensitivity analyses. Coupled with the much lower NNC of 38 for radical nephrectomy complications, there is moderate evidence to support its centralisation.

1
2
3 In our analyses, the mortality reduction for venous thrombectomy was observed to be more
4
5 pronounced than that in radical nephrectomy. This is consistent with the “practice makes
6
7 perfect” hypothesis particularly as venous thrombectomy is a technically more challenging
8
9 procedure compared to radical nephrectomy, though interestingly a similar trend was not
10
11 observed for partial nephrectomy [49]. These results should however be interpreted taking
12
13 into consideration that only a few studies have so far reported on the volume-outcome
14
15 relationships for partial nephrectomy and venous thrombectomy and the pooled effect
16
17 estimates were synthesised from just two to three publications, thus the overall evidence is
18
19 weak. As partial nephrectomy has only been widely adopted in the last two decades and
20
21 nephrectomy centralisation also a relatively recent phenomenon, it is likely that more
22
23 evidence will emerge in the coming years and repeating the meta-analysis at such point is
24
25 warranted [1,50]. This will be of particular importance as partial nephrectomy has been
26
27 demonstrated to be a safe procedure and the relatively small number of partial
28
29 nephrectomy patients in our meta-analysis might not have been sufficiently powered to
30
31 reveal the true presence of a volume-outcome relationship, as evident in our wide
32
33 confidence interval [51]. This may also explain the lack of significant association between
34
35 partial nephrectomy complications and hospital volumes. With its low mortality and
36
37 morbidity rates, other outcome measures such as ischaemic time and negative surgical
38
39 margins, are likely to be more appropriate quality markers in volume-outcome analysis, but
40
41 these have so far been poorly evaluated.
42
43
44
45
46
47
48
49
50

51
52 Despite the strict inclusion criteria in our studies, we observed considerable heterogeneity,
53
54 especially in the meta-analyses of nephrectomy complications. One explanation for this is
55
56 the lack of standardised reporting of complications by individual studies. Harder endpoints
57
58
59
60

1
2
3 as previously discussed could have overcome this. Other more objective outcomes including
4
5 transfusion rate and length of stay were reported by four [30,31,35,40] and seven studies
6
7 [30–32,34,39,40,52] in our systematic review respectively, but they were not in adequate
8
9 numbers to be stratified by nephrectomy types or in sufficiently detailed data to perform
10
11 meta-analyses. In addition, variations in the threshold values for HV hospitals likely
12
13 contributed to the heterogeneity, although this was not evident in the meta-regression.
14
15 Volume was also used as a proxy marker for surgical and care quality, but the precise clinical
16
17 processes that may improve patient outcomes were not directly measured or identified. It is
18
19 therefore conceivable for some heterogeneity to arise from these unmeasured practices.
20
21 Results from the multiple sensitivity analyses to adjust for study differences have however
22
23 remained robust and our study would still appear to be informative and relevant. There are
24
25 other research designs that may be more appropriate in testing our hypothesis such as
26
27 analysis of primary data amalgamated from multiple population cohorts. The considerable
28
29 ethical concerns and logistical constraints of this may however be challenging to overcome
30
31 and not practically feasible.
32
33
34
35
36
37
38
39
40

41 While there has been an expansion in the studies on nephrectomy volume-outcome
42
43 relationship, many questions continue to be unanswered. The proportion of nephrectomy
44
45 performed under laparoscopy or robotic assistance is growing [53,54]. There is however a
46
47 paucity of evidence specifically investigating this in the volume-outcome context with only
48
49 one study examining the differences in perioperative measures in robotic partial
50
51 nephrectomy [40]. Three other studies have adjusted surgical techniques in multivariable
52
53 regressions, but these did not directly demonstrate the effect of laparoscopic volumes on
54
55 surgical outcomes [18,30,33]. Due to the small study number and data quality, it was not
56
57
58
59
60

1
2
3 possible in this meta-analysis to further sub-stratify each nephrectomy type into open and
4
5 minimally invasive and our results should be interpreted taking this limitation into account.
6
7

8
9
10 Tumour characteristics including TNM stage and grades are well established to significantly
11
12 affect and predict nephrectomy mortality, but only two studies have so far adjusted for this
13
14 in their analyses [18,29]. Surgeon case volume and degree of specialisation also play
15
16 significant roles in determining operative outcome, and can be more important than hospital
17
18 case volume alone [45,55–57]. While not the focus of this study, no significant association
19
20 was found between surgeon volume and complications in radical nephrectomy [18], but 31%
21
22 and 16% reduction in mortality and complications respectively was observed in partial
23
24 nephrectomy in HV surgeons [41]. HV surgeons performing nephrectomy with venous
25
26 thrombectomy were also reported to have reduced risk of mortality [19], but this was not
27
28 observed in a subsequent study [42]. As our analyses were based on crude pooled effect
29
30 estimates, future meta-analysis should ideally attempt to adjust for other possible
31
32 confounders including patient demographics, socioeconomic status and comorbidities,
33
34 although this may be methodologically challenging. It would be of high interest to
35
36 understand the interactions between patient characteristics, surgeon volume, surgical
37
38 approach, and oncological factors in the volume-outcome relationship and may provide
39
40 additional insights to selecting patients that will benefit the most from nephrectomy
41
42 centralisation, such as those with multiple comorbidities or advanced disease. Similarly, no
43
44 study has examined the long-term benefits of centralising nephrectomy when high volume
45
46 centres have been demonstrated to increase oncological survival in other cancer surgeries
47
48 [58,59]. Results of this may further influence the recommendations for nephrectomy
49
50 centralisation and this is currently being explored in our ongoing work. Other outcomes
51
52
53
54
55
56
57
58
59
60

1
2
3 including long-term risks of chronic kidney disease and cardiovascular morbidities and
4
5 patient reported outcome measures may also provide more relevant and holistic
6
7 measurements of the potential efficacy of nephrectomy centralisation.
8
9

10
11
12 Our secondary analyses would suggest that a minimum volume threshold for nephrectomy
13
14 likely exist, and beyond that, risks of adverse outcomes may continue to decrease with
15
16 further increase in volume. An important limitation of this however is that this minimum
17
18 threshold cannot be objectively determined from the current evidence. The specific care
19
20 processes that may produce good outcomes, such as access to nurse specialists and clinical
21
22 trials, could not be determined from our study. As volume is likely to be a proxy marker for
23
24 quality, increasing volume alone in itself is unlikely to reduce adverse results [60]. Future
25
26 research should concentrate on identifying the qualitative differences between providers in
27
28 order for the contributing good practices to be adopted by lesser performing centres.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CONCLUSIONS

Current evidence of the association between hospitals volumes and nephrectomy outcomes is of low quality with considerable between-study heterogeneity. Our meta-analyses demonstrated significant reductions in mortality and complications for patients undergoing radical nephrectomy in HV hospitals. Evidence of this in partial nephrectomy and nephrectomy with venous thrombectomy is not yet clear but warrants further investigations.

For peer review only

ACKNOWLEDGMENTS

We would like to acknowledge Annie Herbert for providing valuable critiques of the methodologies.

For peer review only

CONTRIBUTORS

RCJH, VJG and JNA contributed to the study conception and design. RCJH, JM and JNA contributed to data acquisition and risk of bias assessment. RCJH, TS, GL, VJG, JNA contributed to statistical analysis, data interpretation and critical manuscript revision. RCJH contributed to drafting the manuscript. RCJH contributed to obtaining funding. GL, VJG and JNA contributed to supervision of the study.

FUNDING STATEMENT

This work was supported by Addenbrooke's Charitable Trust, the Royal College of Surgeons of England and The Urology Foundation.

COMPETING INTEREST STATEMENT

None declared.

DATA SHARING STATEMENT

No additional data are available.

REFERENCES

- 1 National Institute for Clinical Excellence. Guidance on cancer services: Improving outcomes in urological cancers. London: 2002.
- 2 Cooperberg MR, Modak S, Konety BR. Trends in regionalization of inpatient care for urological malignancies, 1988 to 2002. *J Urol* 2007;**178**:2103–8.
- 3 Boudourakis LD, Wang TS, Roman SA, *et al*. Evolution of the surgeon-volume, patient-outcome relationship. *Ann Surg* 2009;**250**:159–65.
- 4 Birkmeyer JD, Lucas FL, Wennberg DE. Potential benefits of regionalizing major surgery in Medicare patients. *Eff Clin Pract* 1999;**2**:277–83.
- 5 Nguyen NT, Paya M, Stevens CM, *et al*. The relationship between hospital volume and outcome in bariatric surgery at academic medical centers. *Ann Surg* 2004;**240**:586–93.
- 6 Pieper D, Mathes T, Neugebauer E, *et al*. State of evidence on the relationship between high-volume hospitals and outcomes in surgery: a systematic review of systematic reviews. *J Am Coll Surg* 2013;**216**:1015–25.
- 7 Trinh QD, Bjartell A, Freedland SJ, *et al*. A systematic review of the volume-outcome relationship for radical prostatectomy. *Eur Urol* 2013;**64**:786–98.
- 8 Hounscome LS, Verne J, McGrath JS, *et al*. Trends in operative caseload and mortality rates after radical cystectomy for bladder cancer in England for 1998–2010. *Eur Urol* 2015;**67**:1056–62.
- 9 Finlayson SR, Birkmeyer JD, Tosteson AN, *et al*. Patient preferences for location of care: implications for regionalization. *Med Care* 1999;**37**:204–9.
- 10 Ferlay J, Soerjomataram I, Ervik M, *et al*. GLOBOCAN 2012 v1.0, Cancer Incidence and

- 1
2
3 Mortality Worldwide: IARC CancerBase No. 11. 2013.<http://globocan.iarc.fr> (accessed
4
5 13 Feb2017).
6
7
- 8 11 Hollingsworth JM, Miller DC, Daignault S, *et al.* Rising incidence of small renal masses:
9
10 A need to reassess treatment effect. *J Natl Cancer Inst* 2006;**98**:1331–4.
11
12
- 13 12 Chow W, Dong L, Devesa S. Epidemiology and risk factors for kidney cancer. *Nat Rev*
14
15 *Urol* 2010;**7**:245–57. doi:10.1038/nrurol.2010.46.Epidemiology
16
17
- 18 13 Znaor A, Lortet-Tieulent J, Laversanne M, *et al.* International variations and trends in
19
20 renal cell carcinoma incidence and mortality. *Eur Urol* 2015;**67**:519–30.
21
22
- 23 14 Tan H-J, Norton EC, Ye Z, *et al.* Long-term Survival Following Partial vs Radical
24
25 Nephrectomy Among Older Patients With Early-Stage Kidney Cancer. *JAMA*
26
27 2012;**307**:1629–35.
28
29
- 30 15 Kim SP, Thompson RH, Boorjian S a, *et al.* Comparative effectiveness for survival and
31
32 renal function of partial and radical nephrectomy for localized renal tumors: a
33
34 systematic review and meta-analysis. *J Urol* 2012;**188**:51–7.
35
36
- 37 16 Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews
38
39 and meta-analyses: the PRISMA statement. *PLoS Med* 2009;**6**:e1000097.
40
41
- 42 17 Jüni P, Holenstein F, Sterne J, *et al.* Direction and impact of language bias in meta-
43
44 analyses of controlled trials: empirical study. *Int J Epidemiol* 2002;**31**:115–23.
45
46
- 47 18 Yasunaga H, Yanaihara H, Fuji K, *et al.* Influence of hospital and surgeon volumes on
48
49 operative time, blood loss and perioperative complications in radical nephrectomy. *Int*
50
51 *J Urol* 2008;**15**:688–93.
52
53
- 54 19 Yap SA, Horovitz D, Alibhai SMH, *et al.* Predictors of early mortality after radical
55
56
57
58
59
60

- 1
2
3 nephrectomy with renal vein or inferior vena cava thrombectomy - a population-
4 based study. *BJU Int* 2012;**110**:1283–8.
5
6
7
8 20 Awopetu a. I, Moxey P, Hinchliffe RJ, *et al.* Systematic review and meta-analysis of
9 the relationship between hospital volume and outcome for lower limb arterial surgery.
10 *Br J Surg* 2010;**97**:797–803.
11
12
13 21 Holt PJE, Poloniecki JD, Loftus IM, *et al.* Meta-Analysis and Systematic Review of the
14 Relationship between Hospital Volume and Outcome Following Carotid
15 Endarterectomy. *Eur J Vasc Endovasc Surg* 2007;**33**:645–51.
16
17
18
19
20
21
22
23 22 Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? a
24 systematic review and methodologic critique of the literature. *Ann Intern Med*
25
26
27
28
29
30
31 23 Mayer EK, Purkayastha S, Athanasiou T, *et al.* Assessing the quality of the volume-
32 outcome relationship in uro-oncology. *BJU Int* 2009;**103**:341–9.
33
34
35
36 24 StataCorp. Stata Statistical Software: Release 14. 2015.
37
38
39 25 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*
40
41
42
43
44 26 Higgins JPT, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses.
45
46
47
48
49 27 Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-
50 analyses of controlled trials with binary endpoints. *Stat Med* 2006;**25**:3443–57.
51
52
53
54 28 Duval S, Tweedie R. A Nonparametric ‘Trim and Fill’ Method of Accounting for
55
56
57
58
59
60

- 1
2
3 29 Hjelle KM, Johannesen TB, Beisland C. Postoperative 30-day Mortality Rates for
4
5 Kidney Cancer Are Dependent on Hospital Surgical Volume: Results from a Norwegian
6
7 Population-based Study. *Eur Urol Focus*;:1–8.
8
9
10 30 Becker A, Bianchi M, Hansen J, *et al.* Benefit in regionalization of care for patients
11
12 treated with nephrectomy: a Nationwide Inpatient Sample. *World J Urol*
13
14 2014;**32**:1511–21.
15
16
17 31 Sun M, Bianchi M, Trinh Q-D, *et al.* Hospital volume is a determinant of postoperative
18
19 complications, blood transfusion and length of stay after radical or partial
20
21 nephrectomy. *J Urol* 2012;**187**:405–10.
22
23
24 32 Hanchanale VS, Javlé P. Impact of hospital provider volume on outcome for radical
25
26 urological cancer surgery in England. *Urol Int* 2010;**85**:11–5.
27
28
29 33 Yasunaga H, Yanaihara H, Fuji K, *et al.* Impact of hospital volume on postoperative
30
31 complications and in-hospital mortality after renal surgery: data from the Japanese
32
33 Diagnosis Procedure Combination database. *Urology* 2010;**76**:548–52.
34
35
36 34 Mitchell RE, Lee BT, Cookson MS, *et al.* Radical nephrectomy surgical outcomes in the
37
38 University HealthSystem Consortium data base: impact of hospital case volume,
39
40 hospital size, and geographic location on 40,000 patients. *Cancer* 2009;**115**:2447–52.
41
42
43 35 Davenport K, Timoney AG, X KF, *et al.* A 3-year review of The British Association of
44
45 Urological Surgeons Section of Endourology Laparoscopic Nephrectomy Audit. *BJU Int*
46
47 2006;**97**:333–7.
48
49
50 36 Keoghane SR, Keeley FX, Timoney AG, *et al.* The British Association of Urological
51
52 Surgeons section of endourology audit of laparoscopic nephrectomy. *BJU Int*
53
54 2004;**94**:577–81.
55
56
57
58
59
60

- 1
2
3 37 Taub DA, Miller DC, Cowan JA, *et al.* Impact of surgical volume on mortality and length
4 of stay after nephrectomy. *Urology* 2004;**63**:862–7.
5
6
7
8 38 Birkmeyer JD, Siewers AE, Finlayson EVA, *et al.* Hospital volume and surgical mortality
9 in the United States. *N Engl J Med* 2002;**346**:1128–37.
10
11
12
13 39 Couapel J-P, Bensalah K, Bernhard J-C, *et al.* Is there a volume–outcome relationship
14 for partial nephrectomy? *World J Urol* 2014;**32**:1323–9.
15
16
17
18 40 Monn MF, Bahler CD, Flack CK, *et al.* The impact of hospital volume on postoperative
19 complications following robot-assisted partial nephrectomy. *J Endourol*
20
21 2014;**28**:1231–6.
22
23
24
25
26 41 Abouassaly R, Finelli A, Tomlinson GA, *et al.* Volume-outcome relationships in the
27 treatment of renal tumors. *J Urol* 2012;**187**:1984–8.
28
29
30
31 42 Toren P, Abouassaly R, Timilshina N, *et al.* Results of a national population-based
32 study of outcomes of surgery for renal tumors associated with inferior vena cava
33 thrombus. *Urology* 2013;**82**:572–7.
34
35
36
37
38 43 Withington JM, Charman SC, Armitage JN, *et al.* Hospital Volume Does Not Influence
39 the Safety of Percutaneous Nephrolithotomy in England: A Population-Based Cohort
40 Study. *J Endourol* 2015;**29**:899–906.
41
42
43
44 44 Lariviere CA, McAteer JP, Huaco JA, *et al.* Outcomes in pediatric surgery by hospital
45 volume: A population-based comparison. *Pediatr Surg Int* 2013;**29**:561–70.
46
47
48
49
50
51 45 Eskander A, Merdad M, Irish JC, *et al.* Volume-outcome associations in head and neck
52 cancer treatment: a systematic review and meta-analysis. *Head Neck* 2014;**36**:1820–
53
54
55
56 34.
57
58
59
60

- 1
2
3 46 Strom JB, Wimmer NJ, Wasfy JH, *et al.* Association between operator procedure
4 volume and patient outcomes in percutaneous coronary intervention: a systematic
5 review and meta-analysis. *Circ Cardiovasc Qual Outcomes* 2014;**7**:560–6.
6
7
8
9
10 47 Hata T, Motoi F, Ishida M, *et al.* Effect of hospital volume on surgical outcomes after
11 pancreaticoduodenectomy. *Ann Surg* 2016;**263**:664–72.
12
13
14 48 Boogaarts HD, van Amerongen MJ, de Vries J, *et al.* Caseload as a factor for outcome
15 in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. *J*
16 *Neurosurg* 2014;**120**:605–11.
17
18
19
20
21
22
23 49 Luft HS, Hunt SS, Maerki SC. The volume-outcome relationship: practice-makes-
24 perfect or selective-referral patterns? *Health Serv Res* 1987;**22**:157–82.
25
26
27
28 50 Herr H. A history of partial nephrectomy for renal tumours. *J Urol* 2005;**173**:705–8.
29
30
31 51 Corman JM, Penson DF, Hur K, *et al.* Comparison of complications after radical and
32 partial nephrectomy: Results from the National Veterans Administration Surgical
33 Quality Improvement Program. *BJU Int* 2000;**86**:782–9.
34
35
36
37
38 52 Hollenbeck BK, Taub D a, Miller DC, *et al.* Use of nephrectomy at select medical
39 centers--a case of follow the crowd? *J Urol* 2006;**175**:670–4.
40
41
42
43 53 Nuttall M, Cathcart P, van der Meulen J, *et al.* A description of radical nephrectomy
44 practice and outcomes in England: 1995-2002. *BJU Int* 2005;**96**:58–61.
45
46
47
48 54 Fedeli U, Novara G, Alba N, *et al.* Trends from 1999 to 2007 in the surgical treatments
49 of kidney cancer in Europe: Data from the Veneto Region, Italy. *BJU Int*
50 2010;**105**:1255–9.
51
52
53
54
55
56 55 Birkmeyer J, Stukel T, Siewers A, *et al.* Surgeon volume and operative mortality in the
57
58
59
60

- 1
2
3 United States. *N Engl J Med* 2003;**349**:2117–27.
4
5
6 56 Brusselsaers N, Mattsson F, Lagergren J. Hospital and surgeon volume in relation to
7
8 long-term survival after oesophagectomy: systematic review and meta-analysis. *Gut*
9
10 2014;**63**:1393–400.
11
12
13 57 Sahni NR, Dalton M, Cutler DM, *et al.* Surgeon specialization and operative mortality
14
15 in United States: retrospective analysis. *BMJ* 2016;**354**:i3571.
16
17
18 58 Birkmeyer JD, Sun Y, Wong SL, *et al.* Hospital volume and late survival after cancer
19
20 surgery. *Ann Surg* 2007;**245**:777–83.
21
22
23 59 Gooiker GA, Van Gijn W, Wouters MWJM, *et al.* Systematic review and meta-analysis
24
25 of the volume-outcome relationship in pancreatic surgery. *Br J Surg* 2011;**98**:485–94.
26
27
28 60 Berger DH, Ko CY, Spain DA, *et al.* Society of University Surgeons position statement
29
30 on the volume-outcome relationship for surgical procedures. *Surgery* 2003;**134**:34–40.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SUPPORTING INFORMATION CAPTIONS

Appendix 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.

Appendix 2. Literature search algorithm used in Medline, Embase and the Cochrane Library.

Appendix 3. Breakdown of quality assessment scores for each study included in the review.

Appendix 4. Results of meta-regression investigating the potential explanatory variables for the heterogeneity in the meta-analyses for mortality in **A.** radical nephrectomy and **B.** partial nephrectomy.

Appendix 5. List of excluded studies after full-text review and justifications.




Fig 1. Flow chart of the article selection process.

122x128mm (300 x 300 DPI)






Fig 2. Forest plots displaying the pooled effect estimates of nephrectomy mortality in HV and LV hospitals for A. radical nephrectomy B. partial nephrectomy C. nephrectomy with venous thrombectomy.

100x105mm (300 x 300 DPI)




Fig 3. Contour-enhanced funnel plot of studies analysing hospital volume-outcome relationship in radical nephrectomy mortality. Harbord's modified test for funnel plot asymmetry was not statistically significant.

111x80mm (300 x 300 DPI)




Fig 4. Forest plots displaying the pooled effect estimates of nephrectomy complications in HV and LV hospitals for A. radical nephrectomy B. partial nephrectomy.

101x66mm (300 x 300 DPI)



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Report on page
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	7
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7-9
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7-8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7-8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	9-10



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Report on page
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	10
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	10-11
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	12
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	12-14
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	12-14
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	15-18
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	15-18
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	15-18
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	15-19
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	20
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	21-23
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	21-25
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	27

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e100097
doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Appendix 2. Literature search algorithm for Medline, Embase and the Cochrane Library.

Medline

Nephrectomy Terms:

1. exp Nephrectomy/
2. nephrectom*.mp.
3. (kidney* adj5 (excision* or remov*)).mp.
4. 1 or 2 or 3

Surgeon or Hospital Volume Terms

5. ((physician* or urol* or surg* or operat* or hospital* or procedure*) adj5 (volume* or workload* or caseload* or performance* or number*)).mp.
6. exp Hospitals/
7. exp Surgeons/
8. (volume* or workload* or caseload* or performance*).mp.
9. exp Workload/
10. 6 and 8
11. 7 and 8
12. 6 and 9
13. 7 and 9
14. exp Centralized Hospital Services/
15. centrali*ation.mp.
16. 5 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15

Outcome Terms

17. exp "Outcome Assessment (Health Care)"/
18. exp Patient Outcome Assessment/
19. exp "Outcome and Process Assessment (Health Care)"/
20. outcome.mp.
21. exp Treatment Outcome/
22. exp Mortality/
23. mortalit*.mp.
24. exp Morbidity/
25. morbidit*.mp.
26. exp "Length of Stay"/
27. length of stay.mp.
28. ((duration or length or period) adj5 (stay or hospital*)).mp.
29. exp Survival/
30. survival.mp.
31. exp Patient Readmission/
32. readmission.mp.
33. exp Postoperative Complications/
34. complication*.mp.
35. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
36. 4 and 16 and 35

Embase

Nephrectomy Terms:

1. exp Nephrectomy/
2. exp Partial nephrectomy/
3. exp "Patient history of nephrectomy"/
4. nephrectom*.mp.
5. (kidney* adj5 (excision* or remov*)).mp.
6. 1 or 2 or 3 or 4 or 5

Surgeon or Hospital Volume Terms

7. ((physician* or urol* or surg* or operat* or hospital* or procedure*) adj5 (volume* or workload* or caseload* or performance* or number*)).mp.
8. exp Hospital/

9. exp Surgeon/
10. (volume* or workload* or caseload* or performance*).mp.
11. exp Workload/
12. 8 and 10
13. 9 and 10
14. 8 and 11
15. 9 and 11
16. exp Centralization/
17. centrali*ation.mp.
18. 7 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17

Outcome Terms

19. exp Outcome Assessment/
20. exp Treatment Outcome/
21. outcome.mp.
22. exp Mortality/
23. mortalit*.mp.
24. exp Morbidity/
25. morbidit*.mp.
26. exp "Length of Stay"/
27. length of stay.mp.
28. ((duration or length or period) adj5 (stay or hospital*)).mp.
29. exp Survival/
30. survival.mp.
31. exp Hospital readmission/
32. readmission.mp.
33. exp Postoperative Complications/
34. complication*.mp.
35. 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
36. 6 and 18 and 35

Cochrane Library

Nephrectomy Terms:

1. exp Nephrectomy/
2. nephrectom*
3. kidney* near (excision* or remov*)
4. 1 or 2 or 3

Surgeon or Hospital Volume Terms

5. (physician* or urol* or surg* or operat* or hospital* or procedure*) near (volume* or workload* or caseload* or performance* or number*)
6. exp Hospitals/
7. exp Surgeons/
8. volume* or workload* or caseload* or performance*
9. exp Workload/
10. 6 and 8
11. 7 and 8
12. 6 and 9
13. 7 and 9
14. exp Centralized Hospital Services/
15. centrali*ation
16. 5 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15

Outcome Terms

17. exp "Outcome Assessment (Health Care)"/
18. exp Patient Outcome Assessment/
19. exp "Outcome and Process Assessment (Health Care)"/
20. outcome
21. exp Treatment Outcome/
22. exp Mortality/

- 1
- 2
- 3
- 4 23. mortalit*
- 5 24. exp Morbidity/
- 6 25. morbidit*
- 7 26. exp "Length of Stay"/
- 8 27. length of stay
- 9 28. (duration or length or period) near (stay or hospital*)
- 10 29. exp Survival/
- 11 30. survival
- 12 31. exp Patient Readmission/
- 13 32. readmission
- 14 33. exp Postoperative Complications/
- 15 34. complication*
- 16 35. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
- 17 36. 4 and 16 and 35
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Appendix 3. Breakdown of quality assessment scores for each study included in the review.

Author	Cohort representative (1)	Number of hospital/ surgeons (2)	Sample size (1)	Number of adverse events (2)	Unit of analysis (3)	Patient selection appropriate (2)	Volume categories (1)	Risk adjustment (3)	Clinical processes of care (2)	Outcomes (1)	Total (18)
Alle et al	1	1	1	1	0	1	1	2	0	0	8
Chacker/Sun et al	1	2	1	2	0	0	1	1	0	1	9
Guapel et al	0	2	0	1	0	0	1	2	1	1	8
Donn et al	1	2	1	2	0	0	1	1	0	1	9
Green et al	1	2	0	2	3	0	1	1	0	1	11
Guassaly et al	1	2	1	2	3	0	1	1	0	1	12
Pop et al	1	2	0	1	2	0	1	3	0	1	11
Chanale et al	1	2	1	2	0	0	1	1	0	1	9
Sunaga et al	1	2	1	2	0	0	1	1	0	1	9
itchell et al	1	2	1	2	0	0	1	1	0	1	9
Sunaga et al 2008	0	2	1	2	2	0	1	2	0	1	11
venport et al	0	2	0	1	0	0	0	0	0	1	4
goghane et al	0	1	0	1	0	0	0	0	0	1	3
ub et al	1	2	1	2	0	0	1	1	0	1	9
kmeyer et al	0	2	1	2	0	0	1	1	0	0	7

Appendix 4. Results of meta-regression investigating the heterogeneity in the meta-analyses for mortality and its potential explanatory variables in **A.** radical nephrectomy and **B.** partial nephrectomy.

A.

Explanatory Variable	Regression Coefficient	95% Confidence Interval	p Value
Study year	0.96	0.88, 1.04	0.24
Country of Study			
England	1.46	0.70-3.02	0.24
Japan	0.76	0.28-2.04	0.50
Norway	0.42	0.10-1.76	0.18
USA	1.06	0.51, 2.21	0.85
Data type			
Administrative	1.36	0.71, 2.61	0.28
Clinical	0.74	0.38, 1.32	0.28
Number of patients	1.00	1.00, 1.00	0.45
Number of hospitals	1.00	1.00, 1.00	0.14
Patient age (mean)	0.92	0.70, 1.19	0.36
Patient gender (% of male)	0.96	0.88, 1.05	0.25
Threshold for HV hospitals	0.99	0.99, 1.00	0.01

B.

Explanatory Variable	Regression Coefficient	95% Confidence Interval	p Value
Study year	0.96	0.80, 1.14	0.51
Country of Study			
England	1.42	0.46, 4.27	0.40
Japan	1.19	0.67, 2.13	0.41
USA	0.80	0.51, 1.26	0.22
Data type			
Administrative	1.09	0.61, 1.97	0.66
Clinical	0.91	0.51, 1.65	0.66
Number of patients	1.00	1.00, 1.00	0.26
Number of hospitals	1.00	0.99, 1.00	0.80
Patient age (mean)	1.04	0.97, 1.11	0.16
Patient gender (% of male)	0.99	0.80, 1.23	0.87
Threshold for HV hospitals	1.00	0.93, 1.07	0.83

Appendix 5. List of excluded studies after full-text review and justifications.

Reference	Justification
1. Joudi FN, Konety BR. The impact of provider volume on outcomes from urological cancer therapy. <i>J Urol</i> . 2005;174(2):432-438.	Review
2. Joudi FN, Konety BR. The volume/outcome relationship in urologic cancer surgery. <i>Support Cancer Ther</i> . 2004;2(1):42-46.	Review
3. Killen SD, O'Sullivan MJ, Coffey JC, Kirwan WO RH. Provider volume and outcomes for oncological procedures. <i>Br J Surg</i> . 2005;92:389-402.	Review
4. Mayer EK, Purkayastha S, Athanasiou T, Darzi A, Vale JA. Assessing the quality of the volume-outcome relationship in uro-oncology. <i>BJU Int</i> . 2009;103(3):341-349.	Review
5. Nuttall M, Vandermeulen J, Phillips N, et al. a Systematic Review and Critique of the Literature Relating Hospital or Surgeon Volume To Health Outcomes for 3 Urological Cancer Procedures. <i>J Urol</i> . 2004;172(6):2145-2152.	Review
6. Peyronnet B, Couapel J-P, Patard J-J, Bensalah K. Relationship between surgical volume and outcomes in nephron-sparing surgery. <i>Curr Opin Urol</i> . 2014;24(5):453-458.	Review
7. Pieper D, Mathes T, Neugebauer E, Eikermann M. State of evidence on the relationship between high-volume hospitals and outcomes in surgery: a systematic review of systematic reviews. <i>J Am Coll Surg</i> . 2013;216(5):1015-1025.	Review
8. Penson DF. Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better? <i>Urol Oncol</i> . 2006;24(5):460.	Commentary
9. Sugihara T, Yasunaga H, Horiguchi H, et al. Performance comparisons in major uro-oncological surgeries between the USA and Japan. <i>Int J Urol</i> . 2014;21(11):1145-1150.	Volume-outcome relationship not described
10. Fernando A, Fowler S, O'Brien T, et al. Nephron-sparing surgery across a nation - Outcomes from the British Association of Urological Surgeons 2012 national partial nephrectomy audit. <i>BJU Int</i> . 2016;117(6):874-82.	Volume-outcome relationship not described
11. Wang HH, Tejwani R, Zhang H, Wiener JS, Routh JC. Hospital Surgical Volume and Associated Postoperative Complications of Pediatric Urological Surgery in the United States. <i>J Urol</i> . 2015;194(2):506-511.	Paediatric cohort
12. Tinay I, Gelpi-Hammerschmidt F, Leow JJ, et al. Trends in utilisation, perioperative outcomes, and costs of nephroureterectomies in the management of upper tract urothelial carcinoma: A 10-year population-based analysis. <i>BJU Int</i> . 2016;117(6):954-60.	Volume-outcome relationship in nephroureterectomy only
13. Gilbert SM, Dunn RL, Miller DC, Daignault S, Ye Z, Hollenbeck BK. Mortality After Urologic Cancer Surgery: Impact of Non-index Case Volume. <i>Urology</i> . 2008;71(5):906-910.	Overlapping studied period. Eliminated as per rule 2.
14. Joudi FN, Allareddy V, Kane CJ, Konety BR. Analysis of complications following partial and total nephrectomy for renal cancer in a population based sample. <i>J Urol</i> . 2007;177(5):1709-1714.	Overlapping studied period. Eliminated as per rule 2.
15. Konety BR, Allareddy V, Modak S, Smith B. Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better? <i>J Clin Oncol</i> . 2006;24(13):2006-2012.	Overlapping studied period. Eliminated as per rule 2.
16. Trinh QD, Schmitges J, Sun M, et al. Does partial nephrectomy at an academic institution result in better outcomes? <i>World J Urol</i> . 2012;30(4):505-510.	Overlapping studied period. Eliminated as per rule 2.
17. Finlayson EVA, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery: a national study. <i>Arch Surg</i> . 2003;138(7):721-726.	Overlapping studied period. Eliminated as per rule 4.
18. Goodney PP, Stukel TA, Lucas FL, Finlayson EVA, Birkmeyer JD. Hospital volume, length of stay, and readmission rates in high-risk surgery. <i>Ann Surg</i> . 2003;238(2):161-7.	Did not report on mortality/complications
19. Porpiglia F, Mari A, Bertolo R, Antonelli A, Bianchi G, Fidanza F, et al. Partial Nephrectomy in Clinical T1b Renal Tumors: Multicenter Comparative Study of Open, Laparoscopic and Robot-assisted Approach (the RECORd Project). <i>Urology</i> . 2016;89:45-51.	Did not report on mortality/complications